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Abstract 
Toxigenic Vibrio cholerae is the causative organism responsible for cholera, an 
infectious disease characterized by acute watery diarrhea. Cholera toxin (CT), the 
primary virulence factor of V. cholerae, is a prototypical AB5 toxin secreted through the 
type II secretion pathway. Upon secretion, the toxin initiates endocytosis through the 
interaction of the CTB subunit with the GM1 ganglioside receptor on the small intestinal 
cells. In addition to the secretion of the toxin in the free, water-soluble form, V. cholerae 
secrete biologically active CT in association with outer membrane vesicles (OMVs). 
OMVs are naturally released spherical buds of the outer membranes of Gram-negative 
bacteria with an enveloped periplasmic content. Pathogen-derived OMVs are known to 
mediate the delivery of active toxins and other virulence factors to distant host cells.  
In this work, we sought to characterize the association of CT with V. cholerae OMVs 
and the role of CT-GM1 interaction in cellular uptake of vesicles. demonstrated that 
strain 569B releases OMVs that encapsulate CT, and which interact with host cells in 
a GM1-independent mechanism. Here, we have demonstrated that OMV-encapsulated 
CT, while biologically active, does not exist in an AB5 form; rather, the OMVs 
encapsulate two CTA polypeptides. We further investigated the assembly and 
secretion of the periplasmic CT and found that a major fraction of periplasmic CTA does 
not participate in the CT assembly process and instead is continuously encapsulated 
within the OMVs. Additionally, we found that the encapsulation of CTA fragments in 
OMVs is conserved among several Inaba O1 strains. We further found that under 
conditions in which the amount of extracellularly secreted CT increases, the 
concentration of OMV-encapsulated likewise CTA increases. These results point to a 
secondary mechanism for the secretion of biologically active CT that does not depend 
on the CTB-GM1 interaction for endocytosis.  
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Chapter 1  
 
Introduction and Background  
 
1.1 Cholera  
1.1.1 Epidemiology 
Cholera is a severe and often fatal diarrheal disease that affects regions with poor 
water, sanitation, and hygiene conditions (1-3). The first major cholera pandemic 
originated in the Indian subcontinent in 1817 and extended its way to the rest of the 
world (4). Six cholera pandemics began in India from 1817 to 1923 and spread 
throughout Southeast Asia, Africa, and Latin and South America (3). The current 
(seventh) pandemic began in Indonesia in 1961 and spread rapidly across other 
countries in Asia, Europe, Africa and eventually to Latin America in 1991. In more 
recent years, this ongoing cholera pandemic has continued to affect many developing 
countries with several outbreaks including those in Angola, Haiti, Zimbabwe, and 
Yemen (5-7). The World Health Organization (WHO) estimates that there are between 
1.4 to 4.0 million cases of cholera, and 21,000 to 143,000 deaths per year worldwide, 
therefore remaining a major public health problem (8). 
1.1.2 The species and classification 
The Gram-negative Vibrio cholerae is the etiological agent of cholera. V. cholerae 
has been classified into more than 200 serogroups based on their differences in the 
carbohydrate structure of the O antigen in the lipopolysaccharide (LPS) (9). Among 
these, only the O1 and O139 serogroups, which can express cholera toxin (CT), the 
key virulence factor of V. cholerae, are virulent and able to cause epidemic cholera (10, 
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11). V. cholerae O1 strains are further divided into two biotypes, El tor and Classical 
(12). While the first six pandemics were caused by the V. cholerae O1 Classical strains, 
the O1 El Tor biotype is mainly responsible for the most recent pandemic of cholera 
(13-19). The O1 serogroup is also classified into two major serotypes, Inaba and 
Ogawa (20). The only difference in these two serotypes is the presence of a 2-O-methyl 
group on the O antigen polysaccharide of the Ogawa LPS that is not found on Inaba 
LPS (21, 22).  
1.1.3 Infection 
V. cholerae is the natural inhabitant of aquatic ecosystems but it can also infect 
the human body (12, 23). The pathogenesis of V. cholerae begins with the ingestion of 
contaminated food or water. Once in the human body, bacteria experience harsh 
environmental conditions such as acid stress, bile stress, high osmolarity, and the 
alkaline pH of the intestine (24-27). V. cholerae first encounters the acidic stomach 
barrier which kills most of the bacteria. To overcome this low pH condition, bacteria 
induce an adaptive acid-tolerant response (ATR) (28-31). The surviving bacteria then 
pass to the intestinal lumen and penetrate the mucus layer where they produce toxin-
coregulated pilus (TCP) to colonize the small intestinal epithelium (2, 31-33). After 
colonization, the regulatory protein, ToxT, activates the expression of CT (26). TCP 
along with CT are the two major virulence factors of pathogenic V. cholerae. CT 
secretion leads to a massive efflux of electrolyte and water into the intestinal lumen 
causing severe watery diarrhea (34, 35). 
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1.2 Cholera Toxin 
V. cholerae was first isolated from a patient’s stool by Robert Koch, a German 
microbiologist who proposed in 1886 for the first time that the bacteria produce a 
special “poison” which causes the watery diarrheal symptoms of the infections (36). But 
it was not until 70 years later that two groups from India demonstrated that bacteria-
free culture filtrate of V. cholerae was able to induce the cholera-like symptom in the 
intestinal tract of a rabbit (37, 38). About 10 years after these discoveries, Richard 
Finkelstein’s group purified CT (39), which led to the subsequent elucidation of the 
structure of the toxin and its mechanism of action (34, 40).  
1.2.1 Structure 
CT is a prototypical AB5 toxin (84-kDa) consisting of an enzymatic A-subunit (CTA) 
and a homo-pentameric ring of B subunit (CTB5) which are non-covalently linked 
together (Figure 1.1). The A-subunit (28 kDa) is first synthesized as a single 
polypeptide and expresses activity after a proteolytic cleavage (also called “nicking”) at 
residue Arg-192. This process divides CTA into two CTA1 (∼21.8 kDa) and CTA2 (∼5.4 
kDa) subdomains, which remain covalently linked together by a disulfide bond. CTA1 
is responsible for toxin’s ADP-ribosyltransferase activity, and the alpha-helical CTA2 
tethers the CTA1 to CTB5 (34, 41-43). Heat-labile enterotoxin (LT) is another AB5 toxin 
that is produced by enterotoxigenic Escherichia coli and has about 80% amino acid 
sequence similarity to CT (44, 45).  
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Figure 1.1 Crystal structure of CT.   (A) Side view of CT. The CTA subunit is shown in 
red (CTA1 in dark red and CTA2 in light red) and the CTB pentamer is shown in blue. 
(B) Top view of CTB5. Each CTB subunit is shown in a different color (46). 
 
1.2.2 Assembly and Secretion 
CT is secreted through a two-stage, type II secretion (T2S) process (47). In the 
first step, the A and B subunits that are initially synthesized as precursor peptides in 
the cytoplasm, are translocated across the inner membrane through a sec-dependent 
pathway into the periplasmic space. Then, the subunits fold and assemble into the fully 
formed CT holotoxin. The extracellular protein secretion (Eps) operon recognizes the 
pentameric CTB5, which carries the secretion signal, and exports CT across the outer 
membrane to the extracellular space (48, 49). 
1.2.3 Internalization Mechanism 
Once CT is secreted, each CTB subunit binds with high affinity to a GM1 
ganglioside, a lipid enriched in caveolae/lipid raft regions of the plasma membrane of 
target cells. This interaction triggers the endocytosis of the CT-GM1 complex (50-
52). The binding affinity (KD) of CT for GM1 has been measured to be 4.61 × 10-
12 M using surface plasmon resonance (53). Similar to CT, the B subunits of LT binds 
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to GM1 receptor. However, unlike CT that only utilizes GM1 as its receptor, LT has 
been found to bind to other gangliosides and cell surface galactoproteins as well (54).  
It has been proposed that depending on the cell type that CT is targeting, the 
endocytosis pathway for CT-GM1 complex could be different. Early studies on the 
uptake mechanism of CT suggested that caveolae are involved in endocytosis of the 
toxin in different cell types including rat liver, HeLa, 3T3 and BHK (55-59). However, 
later studies demonstrated that CT can be also internalized through clathrin-dependent 
and clathrin-independent (noncaveolar) mechanisms in some cell types (60-62).   
Upon entry to the host cell, the CT-GM1 complex is trafficked from the plasma 
membrane in a retrograde fashion and through the trans-Golgi network into the 
endoplasmic reticulum (ER) (59, 63). Once in ER, the enzymatic CTA1 disassociates 
from the rest of the toxin through the ER chaperone, protein disulfide isomerase (PDI). 
Then, CTA1 unfolds and hijacks the ER-associated degradation (ERAD) or 
degradosome machinery that retro-translocates misfolded proteins from the ER to the 
cytosol for disposal. Because of its low lysine content, CTA1 escapes proteolysis 
through the degradosome and reaches the cytosol (64, 65). During the endocytosis of 
CT, there is a characteristic lag period between the time that the toxin binds to the host 
cell surface and when it induces activity. This lag phase corresponds to the time that it 
takes to be translocated into the ER and dislocate CTA1 to the cytosol (66). 
After reaching the cytosol, CTA1 catalyzes the ADP–ribosylation of GSa, the 
human signaling protein, which keeps adenylyl cyclase (AC) in the GTP-bound state 
(67). This increases the activity of adenylyl cyclase and therefore elevates the 
intracellular cAMP level. This, in turn, activates a chloride channel, the cystic fibrosis 
transmembrane regulator (CFTR), which leads to an efflux of ions followed by a water 
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secretion into the intestinal lumen, inducing severe watery diarrhea that is characteristic 
of cholera (Figure 1.2). (59, 63). 
   
 
Figure 1.2 Mechanism of action of CT. CTB subunit binds GM1 receptor on the surface 
of small intestinal cells that initiates the endocytosis of the CT-GM1 complex. After 
reaching the ER, the CTA1 subunit dissociates from the complex and retro-translocates 
into cytosol where it catalyzes the ADP–ribosylation of GSa. This activates the AC and 
increases the intracellular cAMP level leading to a massive efflux of ions and water.  
1.3 Outer Membrane Vesicles  
Outer membrane vesicles (OMVs) are spherical particles naturally released from 
the outer membrane (OM) of both pathogenic and non-pathogenic Gram-negative 
bacteria (68, 69). OMVs were first discovered by chance in the mid-1960s in Gram-
negative E. coli under lysine-limiting conditions but were later detected in many other 
Gram-negative species as well as Gram-positive bacteria and archaea (70-72). OMVs 
are extracellularly secreted during the growth of the bacteria, not as a cell death by-
product, and range in size from 25 to 250 nm in diameter (69, 73). The secretion of 
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OMVs is an important mechanism through which bacteria interact with their 
environment. OMVs improve their survival and growth of bacteria by involving in a 
variety of roles including bacterial pathogenesis, stress response, quorum sensing, 
nutrient acquisition, and biofilm formation (68, 69, 72, 74).   
1.3.1 Biogenesis  
OMVs are formed as a result of an upward bulging of the OM and pinching off and 
detachment from the peptidoglycan (PG) (68, 75, 76). Most of the research on OMVs 
are mainly focused on their mechanism of interaction with the host cells and their 
potential biotherapeutic applications. However, the molecular mechanism of OMV 
formation is not clear yet. Several mechanisms have been proposed to describe the 
biogenesis of OMVs, however, these studies cannot explain the release of vesicles 
under normal growth conditions (77, 78). The first model that was described suggested 
that vesicles are formed because of the dissociation of the OM from the underlying PG 
in regions lacking a crosslink (79). Lpp, for instance, is a lipoprotein that contributes to 
the stability of the bacteria by covalently crosslinking PG and the OM. 
Hypervesiculation has been observed in lpp-mutant strains of E. coli suggesting the 
importance of these linkages in OMV biogenesis (68, 80, 81). A second model is that 
the accumulation of biomolecules such as misfolded proteins in the periplasmic region 
is causing a turgor pressure on the OM, making the OM bulge upward and eventually 
pinch off (82, 83). A third model is relying on membrane curvature inducing molecules 
that destabilize the OM and trigger the formation of OMVs. The outer leaflet of the OM 
is mainly composed of negatively charged lipopolysaccharide (LPS) that are 
neutralized by divalent cations. In Pseudomonas aeruginosa, it is hypothesized that the 
interaction of Pseudomonas quinolone signal (PQS) molecules with divalent cations 
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increases the anionic repulsion between LPS molecules and increases the release of 
vesicles (77, 84).  
1.3.2 Composition 
As shown in Figure 1.3, OMVs are derived from the OM of Gram-negative bacteria 
and contain a periplasmic lumen. They are mainly composed of LPS, outer membrane 
proteins (OMPs), phospholipids, nucleic acids (DNA and RNA), as well as periplasmic 
content (85). Many studies have compared the protein composition of OMVs with other 
cellular compartments. Because OMVs are derived from the OM they are enriched in 
abundant OMPs (86, 87). However, some OMPs have been reported to be excluded 
from OMVs, suggesting that the incorporation of proteins in OMVs is a selective and 
not random mechanism (85, 88). OMVs were also found to preferentially package 
periplasmic proteins but lack cytoplasmic and inner membrane proteins (89). The 
encapsulation of proteins in OMVs have many benefits for the protein cargo. The OMV-
enclosed protein would be protected from proteolytic degradation by extracellular 
enzymes (88). Additionally, OMVs can transport the active protein cargo to their distant 
destination through adhesins and other molecules associated with the surface of 
OMVs. This could be beneficial especially for proteins lacking a secretory pathway or 
delivery mechanism in their free form. On the other hand, because of the complex 
composition of OMVs, protein cargo may reach their target in a more concentrated 
manner and along with other bacterial components (75, 85, 90, 91). This enable them 
to make a greater impact on their target than being in their individual form. 
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Figure 1.3 Mechanism of secretion of OMVs. OMVs bleb off from the outer membrane 
of Gram-negative bacteria and encapsulate periplasmic cargo.  
 
1.3.3 Virulence factor delivery 
Virulence factors are molecules produced by Gram-negative pathogens that can 
adhere to the surface, invade host cell, and evade host defense systems by 
manipulating host immune response (92, 93). Many virulence factors have also found 
to be associated with OMVs. Vesicles contribute significantly to bacterial pathogenesis 
by delivering multiple active virulence factors such as adhesins, proteases, LPS, and 
toxins to the distant host cells. Surface-associated virulence factors can mediate the 
association of OMVs to the host cells (73). For example, BabA and SabA, two adhesins 
of Helicobacter pylori, have been detected on the surface of OMVs and found to play 
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an important role in the uptake of vesicles (94). In addition to their role in the binding of 
OMVs to the host cell, surface-associated adhesins are suggested to promote 
interaction of bacteria with the host cell. It has been proposed that adhesins may act 
as a bridge between bacteria and host cells, but the exact mechanism is unclear yet 
(76, 95).  
Surface-associated virulence factors can activate the innate immune response. 
For example, LPS, the most abundant virulence factor on the surface of OMVs, can 
trigger the Toll-like receptor 4 (TLR4). Recent studies have shown that OMVs also 
deliver LPS into the cytosol where it binds to its receptor, caspase-11 (96). This 
activates a TLR4-independent inflammatory response that induces a form of lytic 
programmed cell death (97).  
Additionally, toxins from a variety of pathogens have been found to be associated 
with vesicles and induce cytotoxicity through this pathway. Notably, some toxins such 
as the vacuolating cytotoxin A in H. pylori, cytolysin ClyA in Enterohemorrhagic E. coli 
(EHEC), and LT in enterotoxigenic E. coli (ETEC) are preferentially secreted through 
OMVs. The enrichment of the toxins in OMVs suggests that their association with 
OMVs is regulated. Similar to LT, CT has been also reported to be associated with 
OMVs produced by V. cholerae (98-101). 
1.3.4 Mechanism of host cell entry 
The host cell internalization of OMVs appears to be driven by an array of different 
mechanisms, including macropinocytosis, clathrin-mediated endocytosis, caveolin/lipid 
raft-mediated endocytosis, and/or clathrin/caveolin-independent pathways such as 
membrane fusion (101). Macropinocytosis or “cell drinking” is an actin-driven pathway 
that can facilitate the internalization of the extracellular medium. Macropinosomes are 
heterogeneous in size and can be as large as 5 µm in diameter which makes them a 
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suitable route for the uptake of large OMVs (102, 103). However, macropinocytosis is 
a non-specific endocytic pathway and therefore it is unlikely to be the main OMV entry 
mechanism (104). The size of the cargo that can be internalized through clathrin-
mediated endocytosis is in a range of 100 nm in diameter (105). On the other hand, the 
caveolae/lipid raft mediated endocytosis occurs through the invagination of membrane 
rich in cholesterol, sphingolipids, and caveolin of approximately 60-80 nm in diameter 
(95).  
OMVs are generally heterogeneous in size. It has been suggested that the size of 
OMVs is an important factor in the route through which OMVs enter the host cell (106, 
107). A recent study on H. pylori OMVs has demonstrated that micropinocytosis, 
clathrin and caveolae-dependent endocytosis were involved in the internalization of 
OMVs depending on the size of the vesicles. They found that caveolae-mediated 
endocytosis was the preferential entry mechanism of small vesicles ranging from 20 to 
100 nm in diameter. Endocytosis of larger OMVs into host epithelial cells occurred via 
all mechanisms of endocytosis and micropinocytosis (108). 
1.3.5 Role of toxin-receptor interaction on host cell entry  
OMV-associated toxins have shown to play a critical role in the cytotoxicity of 
OMVs. However, the importance of the interaction of OMV-associated toxins with their 
host cell receptors in the host cell uptake mechanism of OMVs seems to vary by 
organism. Hemolysin of EHEC, leukotoxin of Aggregatibacter actinomycetemcomitans, 
and Shiga toxin 2a of the Shiga toxin-producing E. coli are a few examples of OMV-
associated toxins that are not involved in the internalization of OMVs (109-111).  
However, the Kuehn group’s studies on ETEC OMVs have demonstrated that the 
interaction of LT with its GM1 receptor facilitates the internalization of the vesicles (100, 
112). 
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Chapter 2  
 
Research Objectives 
 
The importance of OMVs in bacterial pathogenicity has just begun to be 
understood. Therefore, it is crucial to elucidate the mechanism of association of 
virulence factors with OMVs and the role they play in cellular uptake and cytotoxicity of 
OMVs. This information allows us to design targeted molecules to inhibit this delivery 
mechanism. CT, the major virulence of V. cholerae, that has been only studied in its 
free form for many decades, has been found to be associated with V. cholerae OMVs 
as well (113). In this work, we have performed a series of experiments to characterize 
this association and understand the role of CT in pathogenicity of V. cholerae OMVs.  
In this work we study four specific aims: 
Aim 1: Characterize the OMVs isolated from in vitro cultures of V. cholerae. The 
physiological activity of the 569B OMVs as well as the association of CT with the 
vesicles will be analyzed here.  
Aim 2: Investigate the role of the receptor GM1 ganglioside in host cell uptake of 
569B OMVs. The location of CT in OMVs will be also determined here. 
Aim 3: Study the structure of OMV-associated CT. The association of both CTA 
and CTB subunits with OMVs will be investigated here. A better insight in the assembly 
and secretion process of CT will be gained as well.  
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Aim 4: Determine the role of physiological conditions in association of CT with 
OMVs.   
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Chapter 3  
 
Material and Methods 
 
3.1 Chemicals 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), 1-palmitoyl-2-
oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (POPG), and tetraoleoyl cardiolipin 
(TOCL) were purchased from Avanti Polar Lipids (Alabaster, AL). 
Monosialoganglioside GM1 from bovine brain and CT were purchased from Sigma-
Aldrich® (St. Louis, MO). Rabbit polyclonal antibody against CTA (AB-43) was 
purchased from Advanced Targeting Systems (San Diego, CA, USA). Rabbit polyclonal 
antibody against CT (ab123129) and CTB (ab34992) were obtained from Abcam 
(Cambridge, UK). 
3.2 Strains and culturing conditions 
V. cholerae O1 classical Inaba 569B (ATCC® 25870™), as well as El Tor Inaba 
strains NCTC 8457 (ATCC® 14033™), C6706, N16961, and O395 (provided by Dr. 
John Mekalanos) were used in this study. Cultures were grown in Difco nutrient broth 
(BD, Sparks, MD) unless otherwise stated in the text (all at 37°C with aeration). 
Human fetal small intestinal FHs 74 cells (ATCC® CCL241™) were grown in 
Hybri-care medium (ATCC 46-X™), supplemented with 30 
ng/mL epidermal growth factor (EGF, Sigma-Aldrich®) and 10% fetal bovine serum 
(Sigma-Aldrich®) at 37°C, with 5% CO2. The medium was changed every two to three 
days. 
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3.3 OMV purification  
Vesicles were purified from V. cholerae cultures using a method adapted from the 
method of Schild et al (114). Briefly, late-exponential-phase cultures (OD600 of 0.75 for 
V. cholerae NCTC 8457 and OD600 of 1 for the other four strains) were centrifuged 
(10,000 × g, 10 min, 4°C). The cell-free supernatant from each culture was filter-
sterilized through a 0.45-um pore size filter followed by a 20-fold concentration of the 
supernatant with an Amicon Ultra-15 centrifugal filter device (50 kDa molecular weight 
cut-off, Millipore). The concentrated supernatant was then ultracentrifuged (140,000 
× g, 3 h, 4°C) using a Beckman SW 28 Ti or 55 Ti rotor and the resulting OMV pellet 
was washed with sterile phosphate-buffered saline (PBS). The ultracentrifugation step 
was repeated, and the final vesicle pellet was resuspended in PBS. The samples were 
stored at 4°C and used within a week.  
3.4 Scanning electron microscopy (SEM) 
Isolated OMVs were added to a clean glass coverslip (12 mm diam., Ted Pella) 
and allowed to air-dry overnight. The samples were then fixed in Karnovsky's fixative 
for 2 hr, followed by sequential dehydration with solutions of 35%, 70%, 85%, 95%, and 
100% (v/v) ethanol in ddH2O for 5 min each. To further and preserve the samples, a 
1:1 solution of ethanol: hexamethyldisilazane (HMDS, Sigma-Aldrich) (2 x 15 min) 
followed by 100% HMDS (2 x 15 min) was used. The samples were dried overnight 
and were coated with iridium. The vesicles were then imaged with a Hitachi 4300 SE/N 
at an accelerating voltage of 5 kV. 
3.5 Dynamic light scattering (DLS) 
DLS (ALV/CGS-3 goniometer system) was used to measure the size distribution 
of isolated OMVs.  The radius of the vesicles was estimated using a CONTIN analysis. 
Cumulants method was used to calculate the mean size (z-average) and size 
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distribution (polydispersity index: PDI) of the vesicles at 25°C with a laser at a 
wavelength of 632.8 nm under a scattering angle of 90°. 
3.6 Western blot analysis 
Samples were separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) on an 8-16% mini-protean TGX precast protein gel 
(BioRad) under either non-boiled and non-reduced or boiled and reduced condition. 
The proteins were electrotransferred to a nitrocellulose membrane for 1.5 hr at 45 V 
followed by immersion in blocking buffer (5% non-fat dry milk in TBST). Subsequently, 
the samples were incubated with the primary and secondary antibody (goat anti-rabbit 
immunoglobulin G conjugated to horseradish peroxidase (HRP), 1:5000, Southern 
Biotech). The enhanced chemiluminescence (ECL) reagent kit (Thermo ScientificTM) 
was then used to develop a signal. 
3.7 Estimation of CT concentration in 569B OMVs 
To calculate the concentration of CT in purified 569B OMVs used in this study, a 
dot blot analysis was performed. A serial dilution of purified CT (Sigma-Aldrich®) with 
known concentrations was prepared. Two µL of each standard along with the isolated 
OMVs were spotted on a nitrocellulose membrane. After the membrane dried, it was 
immersed in a blocking buffer. The CT was then detected using a rabbit anti-CT 
polyclonal antibody (1:5000). A standard curve was plotted for the purified CT spots 
and was used to estimate the OMV-associated CT concentration. To calculate the 
fractional protein composition of the OMVs (CT / total protein), the expected 
absorbance at 280 nm (A280) for this CT concentration was divided by measured A280 
of the OMVs. 
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To measure the percentage of OMV-associated CT in the total CT in the culture 
another dot blot assay was performed. Briefly, cells from 100 mL culture of V. cholerae 
569B were harvested by centrifugation. The cell-free filtered supernatant was then 
concentrated about 20-fold using a PES 10 kDa ultrafiltration centrifugal unit (Pierce; 
Thermo scientific) to avoid losing any CT. After ultracentrifugation of the supernatant 
(140,000 × g, 3 h, 4°C) using a Beckman SW 55 Ti rotor, the OMV-free supernatant 
was collected. The OMV pellet was resuspended in the same volume of PBS. The 
samples were concentrated ten-fold using a SpeedVac concentrator (Savant). Two µL 
of each sample along with a serial dilution of CT as standard was then spotted on a 
membrane and CT was detected using a polyclonal anti-CT antibody. 
3.8 Cytotoxicity assays 
A cell morphology assay was used (115) to indirectly measure the OMV-mediated 
increase in cellular cAMP level. This assay relies on scoring the alteration in the cells’ 
morphology on a scale of 1 to 4 from an elongated (spindly) to a rounded form. Briefly, 
4 x 104 of FHs 74 Int cells were grown overnight on a 96-well tissue culture treated plate 
(CELLSTAR®, Greiner Bio-One). Following three washes with Hank’s balanced salt 
solution (HBSS) buffer, cells were incubated in triplicate with 569B OMVs with CT 
concentrations ranging from 5 ng/well to 40 ng/well for 4 hr. The cells were imaged 
using Nikon Eclipse TE2000-U inverted microscope (Nikon Instruments Inc.) at 20× 
magnification. The CT-induced increase in the cAMP level was measured by scoring 
the change in the cells’ morphology on a scale of 1 to 4 based on the percentage of 
cell rounding.  
A Pierce lactate dehydrogenase (LDH) cytotoxicity assay (Thermo Fisher 
Scientific) was performed according to the manufacturer’s instructions to examine the 
cell membrane integrity. Cells were grown on a microplate as described above and 
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treated with CT, 569B OMVs in triplicate for 24 hr. The LDH background activity was 
measured using medium lacking cells. To determine maximum LDH release, cells were 
treated with 10% v/v lysis buffer from the kit for 45 min at 37° C, 5% CO2. 
The biological activity of OMV-associated CT and OMV-free supernatant was also 
compared by incubation of diluted samples of OMVs and OMV-free supernatant with 
cells for 4 hr. The change in cell morphology was scored.   
To assess the role of GM1 in the uptake of vesicles, the cells were treated with 
either OMVs containing 40 ng/well CT or the same mass of OMVs preincubated with 
GM1 (30 min, 25 °C) for 4 hr. The GM1 to CT ratio was 10:1.  
To compare the cytotoxicity of vesicles isolated from 569B, N16961, and C6706 
strains, cells were treated in triplicate with OMVs from each strain diluted in HBSS for 
3 hr. Cells treated with HBSS was used as control.  
3.9 LPS purification 
The purification of LPS from V. cholerae 569B and NCTC 8457 was carried out 
using the hot phenol-water extraction method as described before (116) with some 
modifications. Briefly, the cells were harvested by centrifugation, and the pellet was 
washed twice in PBS and resuspended in hot water. The sample was boiled for 15 min 
and cooled on ice for another 15 min before treatment with DNase and RNase (37°C, 
1 hr) and proteinase K (60°C, overnight). Tris-saturated phenol was then added to the 
solution (65°C, 15 min), and the sample was centrifuged (16,000 x g, 15 min, 4°C). The 
LPS-enriched water phase was collected, and the phenol phase was incubated again 
with hot water (65°C, 15 min), centrifuged again (16,000 x g,15 min, 4°C) and the 
aqueous phase was separated. The two recovered water phases were mixed and 
dialyzed against DI water and subsequently lyophilized.   
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The LPS samples were separated by SDS-PAGE on an 8-16% polyacrylamide gel 
and stained using the Pro-Q Emerald 300 Lipopolysaccharide Gel Stain Kit (Molecular 
Probes), according to the manufacturer's instructions. 
3.10 Lipid dot blot assay  
Lipid dot blot analyses were performed, as described previously (117). On one 
nitrocellulose membrane, two µg of POPE, POPG, TOCL, and purified 569B LPS and 
on another one, two µg of the mentioned lipids along with GM1 were spotted.  The 
membranes were dried under nitrogen, incubated with blocking buffer (5% non-fat dry 
milk in TBS) and then with CT (0.8 µg/mL in blocking buffer) for 1 hr at room 
temperature. Subsequently, the membranes were incubated with polyclonal anti-CT 
followed by secondary antibodies, as described above.  
3.11 Size exclusion chromatography 
To determine if secreted CT have any further interaction with the outer surface of 
OMVs, NCTC 8457 OMVs were incubated with soluble CT for 1 hr at room temperature. 
The sample was then loaded on a Sephadex G-100 column to separate unbound CT 
from OMV-associated CT. The collected fractions were analyzed for CT using a dot 
blot analysis. The polyclonal anti-CT antibody followed by an HRP-conjugated 
secondary antibody was used to detect CT. The relative amount of CT in each dot was 
estimated using ImageJ software (118).  Lipid analysis was also performed for each 
fraction to detect OMVs. Samples were loaded on a 96-well plate in triplicate and the 
lipophilic dye, FM 4-64 (5 µg/mL; Molecular Probes) was added to each fraction. The 
fluorescence (λexcitation = 512 nm, λemission = 620 nm) of each fraction was then measured 
on a microplate reader. 
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3.12 Proteinase K susceptibility assay  
To determine the location of CT on 569B vesicles a proteinase K digestion assay 
was performed as previously described (119, 120). The 569B OMVs were incubated 
with proteinase K (1 mg/mL, 30 min, 37°C) either in the absence or presence of 1% 
SDS. Subsequently, SDS-PAGE and Western blot analysis was carried out for the 
samples using a polyclonal anti-CT antibody. 
3.13 Indirect non-competitive enzyme-linked immunosorbent assay 
(ELISA) 
An indirect non-competitive ELISA was performed to determine the location of the 
CT on vesicles. Briefly, OMVs isolated from V. cholerae strain 569B vesicles were 
treated with 0.1 M EDTA for 2 hr at 37°C to disrupt the membrane. A Maxisorp 96‐well 
microtiter ELISA plate (Nunc) was coated with 200 µL of either intact or EDTA-treated 
OMVs in triplicate, with CT concentrations ranging from 20 ng/well to 160 ng/well. After 
overnight incubation at room temperature, the unbound antigens were washed off the 
plate with three washes with PBS. The nonspecific binding was blocked using 3% fatty 
acid-free bovine serum albumin (BSA), followed by treatment with a polyclonal anti-CT 
antibody and secondary antibody diluted in BSA. After three final washes, 100 µL of 
3,3’,5,5’-tetramethylbenzidene (TMB) substrate solution (Thermo Fisher Scientific) 
was added to each well for 15 min. The reaction was then stopped using 0.16 M sulfuric 
acid, and the absorbance at 450 nm was measured using a Tecan microplate reader.  
3.14 GM1 ELISA 
To further investigate the intravesicular location of CT a GM1 ELISA assay was 
performed as described previously (121). Each well of a microtiter ELISA plate was 
coated with 100 µL of GM1 ganglioside (1.5 µg/mL in PBS) overnight at room 
temperature. The plate was washed three times with PBS, and the non-specific binding 
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sites were blocked by 3% (w/v) fatty acid-free BSA. After three washes, 100 µL of 
serially diluted samples of either CT, CT preincubated with GM1, 569B OMVs, or 569B 
OMVs preincubated with GM1 were added to the wells in triplicate (2 hr, room 
temperature). The CT concentration in each sample ranged from 80 ng/well to 10 
ng/well. The CT:GM1 mass ratio in the GM1-treated wells was 4:1. Following three 
washes with PBS, the plate was incubated with a polyclonal anti-CT antibody and 
secondary antibody. The ELISA was then developed using TMB solution, as described 
above. 
To analyze the presence of CTB inside the vesicles, another GM1 ELISA assay 
was performed. To expose the intravesicular CT, 569B OMVs were lysed with 0.1 M 
EDTA for 2 hr at 37°C. A serial dilution of CT, intact OMVs, and EDTA-treated 569B 
OMVs with CT concentrations ranging from 80 ng/well to 10 ng/well was prepared. After 
incubating the GM1 pre-coated wells of Maxisorp (Nunc) 96-well polystyrene microtiter 
plates with 3% (w/v) fatty acid-free bovine serum albumin (BSA), 100 µL of each sample 
was added to the wells in triplicate (2 hr, room temperature). CT was then detected 
using an anti-CT polyclonal antibody and a secondary antibody, followed by TMB 
solution, as described above. 
3.15 Fluorescent labeling of vesicles 
To fluorescently label the 569B OMVs, fluorescein isothiocyanate (FITC, Sigma-
Aldrich®) was used, as described previously (100, 122). The purified OMVs were 
pelleted (140,000 x g, 3 hr) and resuspended in 0.1 M sodium bicarbonate at pH 9. 
Then the vesicles were incubated with FITC and stirred for 1 h at room temperature on 
a rotator. The vesicles were washed twice with PBS (140,000 x g, 3 hr) to remove 
unbound dye from the labeled vesicles. 
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3.16 Confocal microscopy 
4 x 104 of FHs 74 Intestinal epithelial cells were cultured overnight on a glass-
bottom, poly-L-lysine-coated 96-well plate (ibidi). The wells were incubated with 200 µL 
of 5 µg/mL Alexa Fluor® 555-conjugated WGA (wheat-germ agglutinin; Invitrogen) in 
HBSS with no phenol red for 10 min at 37°C to label the cell plasma membrane. The 
cells were washed twice with HBSS and then incubated with FITC-OMVs or FITC-
OMVs preincubated with GM1 (0.4 ng/ µL, 30 min, 25°C) in HBSS for 2 hr. 
Subsequently, the unbound vesicles were removed, and the cells were washed twice 
with HBSS. Confocal microscopy was carried out using a Nikon C2si+ confocal 
microscope with a 60x oil immersion objective (NA=1.4). The fluorescence was 
recorded at wavelengths of 488 nm (green; FITC), and 561 nm (red; Alexa Fluor 555). 
ImageJ software was used to process the images.  
3.17 Isolation of periplasm, OMVs, and OMV-free supernatant 
To investigate the CT assembly and secretion process, four 100 mL cultures of the 
569B strain were grown to selected time points on the growth curve. The OD600 of the 
cultures were 0.25 (early logarithmic phase), 0.55 (mid logarithmic phase), 0.8 (late 
logarithmic phase), and 1.1 (early stationary phase). Bacteria were harvested at each 
time point by centrifugation (3000 × g, 8 min, 4°C), and the supernatants were saved 
for later analyses. The periplasm was extracted from the bacteria as described before 
(115). Briefly, bacterial pellets from the cultures with OD600 of 0.25, 0.55, 0.8, and 1.1 
were resuspended in 0.5, 1.1, 1.6, and 2.2 mL of TSE buffer (200 mM Tris–HCl, pH 
8.0, 500 mM sucrose, 1 mM EDTA), respectively. The samples were incubated on ice 
for 30 min followed by a centrifugation step (16000 × g, 30 min, 4°C). The supernatants 
containing the periplasmic extracts were then collected. Samples were separated by 
SDS-PAGE under non-boiled and non-reduced conditions, followed by immunoblot 
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analysis with a polyclonal antibody against CT. The loaded samples were normalized 
relative to their OD600 to represent the concentration of CT in the periplasm of an 
average bacterium at each growth phase.  
The 569B vesicles were isolated from the OMV-free supernatant of samples at 
various optical densities using ultracentrifugation, as described before. The vesicle 
pellet was resuspended in the same volume of PBS. The size of OMVs was measured 
using DLS. To estimate the number of OMVs at each point on the growth curve, the 
lipophilic dye, FM 4-64 (5 µg/mL) was then used. The fluorescence (λexcitation = 512 nm, 
λemission = 620 nm) of each sample was measured on a microplate reader. The relative 
concentration of OMVs was then estimated based on the total fluorescence and the 
surface area of each sample. The OMV and OMV-free supernatant samples were then 
separated by SDS-PAGE under non-boiled and non-reduced conditions and were 
subjected to Western blot analysis using a polyclonal anti-CT antibody. 
3.18 Estimation of the concentration of CT subunits in the periplasm 
To estimate the concentration of CTA and CTB in periplasmic fractions, two dot 
blot analyses were performed. On each membrane, two µL of each periplasmic sample 
was spotted. Additionally, known concentrations of CTA on the first blot and CTB on 
the second blot were spotted and served as the standard. The blots were then 
incubated with either an anti-CTA or an anti-CTB antibody, respectively. The 
concentration of CTA and CTB in periplasmic samples were then calculated using 
standard curves that were plotted for the signals from CTA and CTB dots with known 
concentrations.  
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3.19 Statistical Analysis 
Data are presented as mean ± standard deviations (SD) with the indicated sample 
size. Statistical analysis was performed using unpaired two-tailed Student's t-test or 
one-way analysis of variance (ANOVA) followed by the post-hoc Bonferroni test for 
multiple comparisons. P-values < 0.05 were considered statistically significant. 
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Chapter 4  
 
Characterization of V. cholerae 569B OMVs1  
 
4.1 Introduction 
CT is the primary virulence factor of the pathogenic strains of V. cholerae and is 
responsible for the diarrhea characteristic of cholera disease. CT has been extensively 
studied as a free toxin utilizing the two-step T2SS for extracellular secretion. In this free 
form, CT initiates endocytosis through the binding of the CTB subunit to the GM1 
receptor on the surface of the host cell. Recent studies on V. cholerae OMVs have 
found that in addition to its free form, CT could also be found in association with V. 
cholerae OMVs.  
In this chapter, we initiated our study by performing some preliminary experiments 
to characterize V. cholerae OMVs. We extracted OMVs from in vitro cultures of V. 
cholerae and verified their successful isolation by investigating their morphology and 
size distribution. We further confirmed that CT is associated with a toxigenic strain of 
V. cholerae and quantified their concentration using purified CT as standard. 
Additionally, we investigated the physiological activity of OMVs using FHs 74 small 
intestinal epithelial cells.  
It has been demonstrated that 95% of secreted LT, a close relative of CT, is 
associated with ETEC OMVs. To investigate what fraction of secreted CT was 
 
1 Results in this chapter appear in a published work. 123. Rasti ES, Schappert ML, Brown 
AC. Association of Vibrio cholerae 569B outer membrane vesicles with host cells occurs in a 
GM1‐independent manner. Cellular microbiology. 2018.  
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associated with V. cholerae OMVs, we isolated the OMV-associated and free form of 
CT from a V. cholerae 569B culture and compared the concentration of CT in each 
fraction. This was followed by comparing the biological activity of the two forms of the 
toxin.   
4.2 Results 
4.2.1 Isolation of OMVs from V. cholerae 569B culture 
To initiate this study, the CT-expressing O1 Classical Inaba 569B strain of V. 
cholerae was cultured in nutrient broth until the late logarithmic phase. Cells were then 
harvested and the OMVs were isolated from the cell-free supernatants. Scanning 
electron microscopy (SEM) images of the OMVs exhibited spherical vesicles with 
diameters ranging from 60 to 250 nm for 569B OMVs (Figure 4.1). Additionally, DLS 
was used to measure the size of vesicles. The average diameter of the 569B OMVs 
was 198.5 nm with a polydispersity of 0.292. 
 
 
Figure 4.1 SEM micrographs of V. cholerae 569B OMVs.   
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4.2.2 CT is associated with 569B OMVs 
Next, we investigated the association of CT with 569B OMVs. SDS-PAGE was 
performed under boiled and reduced conditions followed by a Western blot analysis 
using a polyclonal anti-CT antibody. Two strong antibody-reactive bands were found, 
with molecular weights of approximately 28 kDa and 18 kDa, confirming the association 
of the toxin with the vesicles (Figure 4.2A).  
Subsequently, to determine what fraction of protein in the OMV is CT (mass CT / 
total protein mass), a dot blot analysis was performed using an anti-CT polyclonal 
antibody (Figure 4.2B). A serial dilution of CT with known mass along with the purified 
569B OMVs was spotted onto a nitrocellulose membrane. The mass of CT in the OMVs 
was estimated by comparing the intensity of the OMV dots with the CT dots. The total 
protein concentration of the OMVs was measured by collecting the absorbance at a 
wavelength of 280 nm (A280) on a NanodropTM spectrophotometer. We found that CT 
comprised 0.5% of the total protein mass of the vesicles. 
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Figure 4.2 Characterization of CT association with 569B OMVs. (A) Western blot 
analysis of V. cholerae 569B OMVs. Two strong anti‐CT polyclonal antibody‐reactive 
bands were found in OMVs verifying the presence of CT in the OMVs. (B) Dot blot 
analysis for calculation of CT concentration in 569B OMVs. The mass of CT present in 
569B OMVs was determined using a serial dilution of CT with known mass as standard. 
 
4.2.3 569B OMVs associate with and are internalized into the intestinal epithelial 
cells.  
Next, we investigated the mechanism of interaction of 569B OMVs with the host 
cell by examining its temperature dependence. FHs 74 intestinal cells were labeled with 
AF555-WGA. Then cells were incubated with AF 488 labeled 569B OMVs either at 
37°C or 4°C for 3 hr.  As shown in Figure 4.3, as expected, OMVs are associated with 
the host cell at 37°C. However, the incubation of the vesicles with the host cell at 4°C 
resulted in a significant decrease in fluorescence intensity of the cells. This result 
confirms the temperature dependence of uptake of OMVs, the hallmark of 
internalization, and suggests that internalization of OMVs is not a passive process.  
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Figure 4.3 Temperature dependence of the host cell uptake mechanism of OMVs. FHs 
74 intestinal epithelial cells were labeled with AF555-WGA (red) and were incubated 
with Alexa Fluor 488-labeled 569B OMVs (green) at either 37°C (A) or 4°C (B) for three 
hours. OMVs were associated with the host cell at 37 C but no binding occurred at 4°C. 
The scale bar in all the figures is 10 µm. 
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4.2.4 OMV-associated CT is biologically active  
To confirm the biological activity of the OMV-associated CT, the 569B OMV-
mediated cytotoxicity was investigated. Epithelial cells were treated with 569B OMVs 
with CT concentrations ranging from 5 ng/well to 40 ng/well for 4 hr. It has been shown 
that the treatment of FHs 74 intestinal epithelial cells with CT induces a dose-
dependent morphological change from an elongated (spindly) to a rounded form (124). 
We found that similar to CT, the 569B OMVs induces a cAMP-dependent effect on cells 
in a dose-dependent manner (Figure 4.4A), which indicates that OMV-associated CT 
is biologically active. The cell morphology was scored on a scale of 1 (spindly) to 4 
(round); quantification of the images in Figure 4.4A is shown in Figure 4.4B.  
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Figure 4.4 V. cholerae 569B OMV‐mediated cytotoxicity. (A) Representative phase-
contrast image of OMV‐treated FHs 74 intestinal epithelial cells. (i) Untreated cells 
and (ii) OMV‐treated cells (0.4 ng/μl of CT, 4 hr). Enlarged views of the regions in 
small boxes are shown in the insets. (B) Quantitative analysis of the OMV‐treated cell 
morphology. Cells were treated with a serial dilution of 569B OMVs (5 to 40 ng CT per 
well), and the resulting morphology scored on a scale of 1 (spindly) to 4 (rounded), 
based on the percentage of cell rounding. Data are expressed as mean ± SD (N = 3). 
One‐way analysis of variance followed by Bonferroni's post hoc test was used to 
compare differences between treated and untreated samples; *p < .05, **p < .01, and 
***p < .001.  
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4.2.5 Comparison of biological activity of OMV-associated CT and OMV-free 
supernatant 
To compare the biological activity of the OMV-associated CT and the OMV-free 
supernatant, the fraction of secreted CT in the supernatant that is associated with 
OMVs was first measured using a dot blot analysis. Both isolated OMVs and the OMV-
free supernatant were spotted on nitrocellulose along with purified CT in a serial dilution 
(Figure 4.5). We estimated that, by mass, about 25% of CT is secreted in a water-
soluble free form, while about 75% of the toxin is associated with OMV.  
 
Figure 4.5 Relative CT concentration in 569B OMVs and OMV‐free supernatant.  Dot 
blot analysis was performed to quantify the concentration of CT in OMV-free 
supernatant and OMVs using a serial dilution of CT with known mass and a polyclonal 
anti-CT antibody. About 75% of the mass of the toxin was found to be associated with 
OMVs. 
 
 
Next, the cytotoxicity of OMV-associated CT was compared with the OMV-free 
supernatant. Cells were treated with the same volume of OMVs and OMV-free 
supernatant, and the CT-mediated cell rounding was scored.  As described above, the 
OMV fraction contained three times more CT than did the supernatant fraction. As 
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shown in Figure 4.6A, OMV-associated CT induced a greater cellular response than 
the supernatant due to the greater mass of CT in the OMVs compared to the 
supernatant. Representative images used for quantification in Figure 4.6B are 
presented in Figure 4.6A demonstrating a similar CT-mediated cell morphological 
alteration proportional to the mass of CT found in each fraction.   
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Figure 4.6 Cytotoxicity of OMVs and OMV-free supernatant.(A) Representative phase 
contrast image of FHs 74 intestinal epithelial cells treated with (i) OMVs and (ii) OMV-
free supernatant.  (B) Quantification of 569B OMV and OMV‐free supernatant‐
mediated cytotoxicity. Cells were treated with purified OMVs or OMV‐free 
supernatant. Control cells were treated with Hank's balanced salt solution. OMV‐
mediated alterations in cell morphology were scored on a scale of 1 (spindly) to 4 
(rounded). Data are expressed as mean ± SD (N = 3). The level of significance was 
determined between cells treated with OMVs and OMV‐free supernatant using an 
unpaired two‐tailed t test. ***p < .001.  
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4.3 Discussion  
In this chapter, we first confirmed that the CT-expressing 569B strain of V. cholerae 
secretes OMVs with size in the range of 200 nm in diameter. Subsequently, we 
demonstrated that CT was associated with 569B OMVs. We found that only about 25% 
of the mass of the secreted CT in a nutrient broth culture of V. cholerae 569B was in 
the free soluble form and most of the toxin was found in association with OMVs.  
We further investigated the interaction of the vesicles with FHs 74 intestinal 
epithelial cells. Previous studies on OMVs have found that the internalization of OMVs 
occurs through an energy-dependent process (122, 125). Here we demonstrated that 
569B OMV internalization into the host cell happens in a temperature-dependent 
manner as well.  
Additionally, our studies on the physiological activity of OMVs revealed that the 
OMV-associated CT induces a cAMP-dependent cell morphological response in FHs 
74 intestinal epithelial cells in a similar manner as free CT. This suggests that the OMV-
associated CT contributes to the cytotoxicity of 569B OMVs.  
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Chapter 5  
 
Association of CT with V. cholerae 569B OMVs2 
 
5.1 Introduction 
The association of a fraction of secreted CT with OMVs and the role that this form 
of the toxin plays in cholera infection is of great importance. CT in its free form is 
secreted into the lumen of the intestines through the T2SS. The host cell internalization 
of CT then occurs through the interaction of the CTB subunits with their GM1 receptor. 
On the other hand, the mechanism of internalization of V. cholerae OMVs and its CT 
delivery is not clear yet. Therefore, it is necessary to gain more insight into this 
mechanism to develop therapeutic agents to inhibit this delivery pathway.  
Studies on LT, a protein that shares many structural and functional similarities with 
CT, have demonstrated that LT has some affinity for LPS, the major component of the 
outer layer of OMVs. Because of this interaction, Kuehn et al have found that secreted 
LT partially resides on the surface of ETEC OMVs. Additionally, their studies on the 
uptake mechanism of ETEC OMVs have revealed that the interaction of OMV-
associated LT, with its receptor, GM1, facilitates the internalization of the vesicles (100, 
112). We hypothesized that, like LT, the interaction of OMV-associated CT with the 
GM1 receptor may play a role in the internalization of V. cholerae vesicles. Therefore, 
in this chapter, we have performed a series of experiments to characterize the 
association of CT with OMVs isolated from nutrient broth cultures of V. cholerae 569B 
 
2 Results in this chapter appear in a published work. 123. Ibid. 
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and to determine whether the CT-GM1 interaction is essential for cellular uptake of 
vesicles.  With knowledge of the essential molecules in this pathway, we will, in the 
future, design targeted molecules to inhibit CT delivery to host cells via OMVs.    
5.2 Result 
5.2.1 CT does not have an affinity for V. cholerae O1 LPS 
The outer leaflet of OMVs is mainly composed of LPS. LT, the close relative of CT, 
is partially associated with the outer surface of ETEC OMVs due to its affinity for LPS 
(112). Considering this finding, we sought to investigate the association of CT for the 
lipids comprising the OMVs using lipid dot blot analysis. In one blot, we compared the 
affinity of CT for the OMV lipids, POPE, POPG, TOCL, and 569B LPS, along with GM1.  
The affinity of CT for GM1 has previously been reported to be 4.6 x 10-12 M by surface 
plasmon resonance (SPR) (53) and 5.2 x 10-8 M by isothermal titration calorimetry (ITC) 
(126). As shown in Figure 5.1A, i, our analysis likewise demonstrated a strong affinity 
of CT for GM1, and only a slight affinity for POPE and TOCL; no affinity for 569B LPS 
or POPG was detected. In another blot, we investigated the affinity of CT for the 
aforementioned OMV lipids in the absence of GM1. Among all OMV lipids, we only 
detected some affinity of CT for POPE (Figure 5.1A, ii) and unlike LT, we detected no 
affinity for LPS. These results indicate that while CT has some affinity for the OMV lipid, 
POPE, this affinity is significantly weaker than the toxin’s affinity for GM1. 
Because the lipids in the dot blot are not in a bilayer structure as they are in the 
OMV, we verified the observed lack of binding to LPS by measuring the binding of CT 
to purified OMVs produced by the NCTC 8457 strain.  This strain does not express CT, 
but is from an O1 serotype, like 569B, with similar LPS structure, which we verified by 
SDS-PAGE analysis (Figure 5.1B).  After incubation of purified toxin with the NCTC 
8457 OMVs, unbound CT was separated from the OMVs using a Sephadex G-100 
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column. The lipid content of each fraction was determined by measuring the 
fluorescence intensity of the lipophilic dye, FM 4-64, and the CT content of each fraction 
was determined by dot blot.  As shown in Figure 5.1C, the OMVs were detected in 
earlier fractions than was the CT, demonstrating that there is no interaction between 
free CT and the outer surface of NCTC 8457 OMVs.  This result is consistent with the 
dot blot results and indicates that CT association with OMVs does not occur via 
interactions with LPS on the OMV surface. 
 
40 
 
 
 
Figure 5.1 Characterization of soluble CT association with OMV lipids. (A) Lipid dot blot 
analysis of CT affinity for (i) POPE, POPG, TOCL, 569B LPS, and GM1, and (ii) POPE, 
POPG, TOCL, and 569B LPS (with no GM1). In the presence of GM1, free CT was 
found to have a strong affinity for GM1, and in absence of GM1, it had some affinity for 
POPE. In both cases, no affinity for 569B LPS was seen. (B) SDS-PAGE analysis of 
purified LPS from V. cholerae 569B and NCTC 8457. Lane 1 is the LPS standard; lane 
2 is 569B LPS; and Lane 3 is NCTC 8457 LPS. (C) Association of CT with OMVs. 
OMVs from a non-CT- expressing strain, NCTC 8457, were purified and incubated with 
CT to characterize the affinity of CT for O1 LPS. Unbound CT was separated from the 
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OMVs using size exclusion chromatography. The lipid (circles) and protein (triangles) 
analysis of the size exclusion chromatography fractions demonstrated that there was 
no association between NCTC 8457 OMVs and soluble CT. 
 
5.2.2 CT is located within the lumen of OMVs 
To investigate the location of CT relative to the 569B vesicles, a proteinase K 
susceptibility assay was performed. Western blot analysis was carried out under 
reduced condition using a polyclonal anti-CT antibody. A strong band along with two 
fainter bands were detected in lane 1 for 569B OMVs that have not been treated with 
either proteinase K or SDS (Figure 5.2).  After proteinase K digestion of vesicles (lane 
2), no change was observed in the intensity of the bands suggesting the absence of 
CT on the outer surface of OMVs. However, disruption of OMVs with SDS prior to 
proteinase K treatment (lane 3), resulted in the disappearance of the faint bands and a 
great decrease in the intensity of the stronger band. This result suggests that OMV-
associated CT is located inside the vesicles.   
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Figure 5.2 Proteinase K digestion of 569B OMVs.  Lane 1: Untreated OMVs. Lane 2: 
Proteinase K‐treated OMVs. Lane 3: SDS‐ and proteinase K‐treated OMVs. 
 
To further verify the above result, we performed an indirect non-competitive ELISA 
assay using the anti-CT polyclonal antibody. A Nunc-Immuno plate was coated with a 
serial dilution of intact or EDTA-disrupted OMVs with CT concentration ranging from 
20 to 160 ng/well. As shown in Figure 5.3, no signal was detected for intact vesicles 
suggesting the absence of CT on the surface of vesicles. On the other hand, a dose-
dependent increase in binding of the antibody to vesicles was observed for EDTA-
disrupted OMVs confirming the intravesicular location of CT. 
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Figure 5.3 Localization of 569B OMV‐associated CT using Indirect noncompetitive 
ELISA.  EDTA‐disrupted OMVs (triangles) bound to the anti‐CT polyclonal antibody-
coated plate, but intact OMVs (squares) did not. Data are shown as mean ± SD (N = 
3). The level of significance was determined using one‐way analysis of variance 
followed by Bonferroni's multiple comparison test showing a statistically significant 
difference between intact and EDTA‐treated 569B OMVs. **p < .01 and ***p < .001.  
 
5.2.3 Association of OMVs with host cells is not GM1‐dependent  
The absence of CT on the surface of OMVs suggests that CT, unlike LT, would be 
unable to bind to its host cell receptor, GM1. To investigate whether GM1 plays a role 
in OMVs trafficking to the host cell, a GM1 ELISA assay was performed. A serial dilution 
of CT, CT preincubated with GM1, 569B OMVs, or 569B OMVs was added to a 
microtiter plate that was pre-coated with GM1. As shown in Figure 5.4A, soluble CT 
bound to coated GM1 in a dose-dependent manner, and pre-treatment of the toxin with 
GM1 resulted in complete inhibition of binding. However, no GM1-binding was detected 
for either untreated or GM1‐pretreated OMVs (Figure 5.4B). These findings 
demonstrate that unlike soluble CT, OMV‐associated CT does not bind to GM1. 
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Figure 5.4 569B OMV association with GM1. (A) GM1 ELISA to measure soluble CT 
binding to GM1. Soluble CT (open circles) binds to coated GM1; CT pretreated with 
GM1 (filled circles) does not bind GM1. Data are shown as mean ± SD (N = 3). The 
level of significance was determined using one‐way analysis of variance followed by 
Bonferroni's multiple comparison test. (B) GM1 ELISA to measure OMV binding to 
GM1. Neither OMVs (open squares) nor GM1‐treated OMVs (filled squares) bind GM1. 
Data are expressed as mean ± SD (N = 3). One‐way analysis of variance indicated no 
significant difference between untreated and GM1‐treated OMVs. 
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To further investigate the role of GM1 in host cell association of OMVs, confocal 
microscopy analysis was performed. After labeling with AF555-WGA, cells were treated 
with FITC-OMVs or FITC-OMVs preincubated with GM1. As shown in Figure 5.5, 
preincubation with GM1 did not inhibit the association of vesicles with the host cells. 
Together, these results demonstrate that the association of 569B OMVs with FHs74 Int 
cells occurs through a GM1‐independent mechanism. 
 
 
Figure 5.5 GM1-dependence of cellular uptake of OMVs.  FHs 74 intestinal epithelial 
cells were labeled with AF555-WGA (red) and 569B OMVs were labeled with FITC 
(green). Both untreated (top) and GM1-treated OMVs (bottom) are internalized by host 
cells within two hrs. The scale bar in all the figures is 50 µm. 
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5.2.4 GM1 does not play a role in the cytotoxicity of OMVs  
To determine whether the preincubation of OMVs with GM1 would impact the 
cytotoxicity of the vesicles, untreated and GM1‐treated OMVs were incubated with 
human FHs 74 Int cells. Both samples induced a similar morphological change (Figure 
5.6A, i and ii, respectively) which resulted in a similar score (Figure 5.6B). This result 
verifies the lack of interaction between 569B OMV and GM1. 
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Figure 5.6 GM1-dependence of cytotoxicity of OMVs.  (A) Phase-contrast image of FHs 
74 intestinal epithelial cells treated with OMVs. (i) Untreated OMVs and (ii) GM1‐
pretreated OMVs (0.4 ng/μl of CT, 4 hr). Both untreated and GM1‐treated OMVs induce 
cell rounding. (B) Quantitative analysis of the morphology of cells treated with untreated 
OMVs or OMVs pretreated with GM1. Data are expressed as mean ± SD (N = 3). No 
significant difference was observed between two samples as determined by an 
unpaired two‐tailed t test. 
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5.3 Discussion  
V. cholerae secretes its primary virulence factor, CT, in two forms, the free 
water-soluble CT and the OMV-associated CT (113). However, the toxin has been 
mostly studied in its free form secreted through the two-step T2S pathway. Our studies 
in chapter 4 demonstrated that when V. cholerae 569B is cultured in nutrient broth, a 
fraction of CT is associated with 569B OMVs. Our results showed that OMVs are 
internalized into intestinal epithelial cells. We found that in its OMV-associated form, 
CT is biologically active and plays an important role in the cytotoxicity of OMVs.  
In this chapter, we wanted to investigate whether CT is involved in the trafficking 
and uptake mechanism of OMVs. We initially hypothesized that after secretion of CT 
through the T2SS, it binds to the surface of OMVs and through an interaction with its 
receptor GM1, it facilitates the endocytosis of OMVs. To test this hypothesis, we first 
characterized the association of CT with 569B OMVs. Surprisingly, we found that free 
CT does not bind to 569B LPS that were isolated from nutrient broth cultures of V. 
cholerae. We also analyzed the interaction of free CT to OMVs isolated from a non-CT 
expressing NCTC 8457 with similar LPS structure to 569B strain. But we did not detect 
any affinity between CT and surface of NCTC 8457 OMVs. 
Our subsequent investigations revealed that the OMV-associated toxin is located 
exclusively within the lumen of the vesicles and therefore is inaccessible to GM1. We 
found that 569B OMVs were unable to bind to GM1 on the host cell surface and are 
trafficked to host cells in a GM1-independent mechanism. This was against our initial 
hypothesis and is implying that only a fraction of secreted CT is delivered to the host 
cell through the well-known CTB-GM1 interaction. Hence, current anti-toxin strategies 
that rely on blocking this interaction may not have an impact on inhibiting the 
cytotoxicity of CT that is delivered to the host cell via OMVs.  
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The intravesicular location of OMV-associated CT was inconsistent with our initial 
hypothesis that CT association with the surface of OMVs would mediate the 
internalization of vesicles through interaction with GM1. Unlike LT, we found no 
interaction between 569B LPS, the major lipid found on the surface of 569B OMVs, and 
CT to facilitate the surface association of the toxin. A previous study on OMVs from V. 
cholerae O395, the classical O1 from Ogawa serotype, has reported that soluble GM1 
inhibits OMV-mediated cAMP production and cytotoxicity (113). This finding is in 
contradiction with our results demonstrating the GM1-independence of cellular uptake 
of OMVs. This difference may be attributed to the difference in LPS structure of 569B 
and O395 OMVs which belong to Inaba and Ogawa serotypes of V. cholerae O1 
serogroup, respectively (20, 127). It has been reported that the structure of the O-
antigen of LPS from these two serotypes is different (21, 22, 128). Therefore, unlike 
the 569B OMVs which have no surface CT due to the lack of CT-LPS interaction, the 
toxin affinity for O395 LPS may allow them to reside on the surface of O395 OMVs 
which in turn leads to internalization of OMVs through the GM1 receptor.  
The internalization mechanism of OMVs from other pathogens has been 
demonstrated to be independent of the toxin-receptor interaction. EHEC hemolysin, V. 
cholerae cytolysin, and cytolethal distending toxin (CDT) expressed by Aggregatibacter 
actinomycetemcomitans and Campylobacter jejuni are a few examples of other OMV-
associated virulence factors that have shown not to be essential for internalization of 
OMVs (109, 110, 129-131). On the other hand, as mentioned before, LT, is located on 
the surface of ETEC OMVs and mediates OMV binding to the GM1 receptor (100, 112).   
OMV-associated CT contributes to the cytotoxicity of 569B OMVs by inducing a 
cAMP-dependent cell morphological response in FHs 74 intestinal cells in a similar 
manner as free CT. This demonstrates that the active subunit of OMV-associated CT 
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(CTA1) has reached its cellular destination, the cytosol. Therefore, although OMVs are 
not taken up through a CT-GM1 dependent mechanism, they are able to efficiently 
deliver active CT to their intracellular target. 
In summary, our findings in this chapter suggest that V. cholerae has a secondary 
mechanism for the secretion of biologically active CT, which does not depend on the 
CTB-GM1 interaction for endocytosis. 
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Chapter 6  
 
CT Encapsulated within Several Vibrio cholerae O1 
Serotype Inaba OMVs Lacks a Functional B-Subunit 3 
 
6.1 Introduction 
The extracellular secretion of CT holotoxin occurs through the T2SS. During this 
process, unfolded CT subunits must first cross the inner membrane and reach the 
bacterial periplasm. After folding and assembly to CTAB5 in the periplasmic space, the 
toxin is recognized by the Eps operon and is translocated across the outer membrane.  
Our findings described in the previous chapter revealed that a fraction of secreted 
CT is in an OMV-associated form and is located exclusively inside the vesicles. This 
location prevents the toxin from being detected by conventional CT-detection assays. 
Therefore, unlike soluble CT, which employs GM1 to initiate cellular internalization, the 
physiologically active OMV-enclosed CT is unable to bind GM1 on the host cell surface 
and is trafficked to the host cells in a GM1-independent mechanism (123). We 
hypothesized that because OMV-encapsulated CT does not interact with cells in the 
same GM1-dependent mechanism of soluble CT, the toxin structure may differ from 
the classic AB5 form.   
 
3 Portions of this chapter appear in a published work and are presented with permission 
from MDPI. 132. Rasti ES, Brown AC. Cholera Toxin Encapsulated within Several Vibrio 
cholerae O1 Serotype Inaba Outer Membrane Vesicles Lacks a Functional B-Subunit. Toxins. 
2019;11(4):207. 
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In this chapter, we characterized the structure of OMV-encapsulated CT and 
investigated the association of specific CT subunits with OMVs to further understand 
this important delivery system. We further assessed the strain-dependence of our 
results by analyzing OMVs from two pandemic O1 El Tor strains, C6706 and N16961.  
 
6.2 Results  
6.2.1 CT encapsulated within V. cholerae 569B OMVs does not have an intact 
CT holotoxin form 
To better characterize CT encapsulated within 569B OMVs isolated from nutrient 
broth culture, we first compared its structure to that of purified CT using Western blot 
under (i) non-boiled and non-reduced, (ii) boiled and non-reduced, or (iii) boiled and 
reduced conditions using a polyclonal anti-CT antibody. As demonstrated in Figure 6.1, 
lane 4, under the (i) non-boiled and non-reduced conditions, the CT sample dissociated 
into a CTB5 pentamer (45 kDa), a CTA-subunit (28 kDa), and a CTB monomer (11.6 
kDa). Under similar conditions, a CTA band (28 kDa) and an unknown band with a 
molecular weight of approximately 18 kDa were detected in the OMVs (lane 1).  
However, no band was detected for CTB5 pentamer in the vesicles. 
Under the (ii) boiled and non-reduced conditions, the CT sample dissociated into a 
CTB monomer and a CTA-subunit, as shown in lane 5. In the corresponding OMV 
sample, the same two bands detected in lane 1 (18 and 28 kDa) were found in lane 2, 
but the intensity of the 18 kDa band was greater in this boiled sample (lane 2) than in 
the non-boiled sample (lane 1). This difference in intensity could be due to the exposure 
of hidden epitopes after complete denaturation of the peptide by boiling.  
Under the (iii) boiled and reduced conditions, CT separated into a reduced CTA1 
domain (21.8 kDa) and a CTB monomer, as shown in lane 6. On the other hand, neither 
 
53 
 
the 28 kDa nor the 18 kDa band detected in the OMV sample was reduced (lane 3). 
Both bands migrated in the same manner as under non-reduced conditions (lane 2). 
Additionally, no CTB was detected in lane 3. These results indicate that the CT 
encapsulated within 569B OMVs isolated from a nutrient broth culture consists of two 
polypeptides of CT but no intact CT holotoxin.  
 
Figure 6.1 Western blot analysis of 569B OMVs and purified CT. Lanes 1 and 4: 569B 
OMVs and CT under non-boiled and non-reduced conditions. Lanes 2 and 5: 569B 
OMVs and CT under boiled and non-reduced conditions. Lanes 3 and 6: 569B OMVs 
and CT under boiled and reduced conditions. Two non-reducible anti-CT antibody‐
reactive bands were detected in 569B OMVs in each condition, but no band 
corresponding to the CTB5 pentamer was detected in the OMV sample.  
 
To confirm that the two bands detected with the anti-CT antibody are not non-CT 
peptides that cross-react with this antibody, vesicles isolated from 569B and non-CT 
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expressing NCTC 8457 strains were analyzed by Western blot under non-boiled and 
non-reduced conditions. The 569B strain expresses CT while NCTC 8457 does not 
(15). As shown in Figure 6.2, neither of the anti-CT reactive bands in the 569B OMVs 
were recognized in NCTC 8457 OMVs. This result supports the finding that the two 28-
kDa and 18-kDa polypeptides associated with 569B OMVs are fragments of CT. 
Because we have previously shown that the OMV-associated CT is biologically active 
and induces the same morphological response as intact CT (123), we hypothesized 
that at least one of these polypeptides contains an active domain of CTA. 
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Figure 6.2 Western blot analysis of OMVs from 569B and NCTC 8457 strains. Lane 
1:569B OMVs under non-boiled and non-reduced conditions. Lane 2: NCTC 8457 
OMVs under non-boiled and non-reduced conditions. Strain NCTC 8457 does not 
express CT. Both anti-CT reactive polypeptides detected in 569B OMVs were absent 
in non-CT expressing NCTC 8457 vesicles.  
6.2.2 The CTB-subunit is not associated with 569B OMV-encapsulated CT 
Next, we wanted to analyze the identity of the two anti-CT reactive polypeptides 
associated with the 569B OMVs. To investigate the presence of CTB in OMVs, a GM1 
ELISA assay was performed using an anti-CT polyclonal antibody.  Because only the 
B-subunit of the intact holotoxin is able to bind GM1 (133), we used this assay to 
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quantify the presence of B-subunit in the OMV-encapsulated CT. We have previously 
demonstrated that when V. cholerae 569B is cultured in a nutrient broth medium, CT is 
located exclusively inside the OMVs and therefore the vesicles do not bind GM1 (123). 
Here we used EDTA-disrupted OMVs and reasoned that if any CTB is enclosed 
within the OMVs, it would be exposed and bind to the GM1-coated plate. Therefore, 
we incubated a GM1-coated plate with a serial dilution of either EDTA-disrupted or 
intact vesicles along with CT as positive control. As we demonstrated before, a dose-
dependent signal was detected for the soluble CT, confirming the binding of the toxin 
to the receptor. However, no GM1 binding was observed for neither intact nor EDTA-
disrupted OMVs. This result suggests that CTB is not associated with OMVs (Figure 
6.3). 
 
Figure 6.3 GM1 ELISA assay for V. cholerae 569B OMV-associated CT.  A GM1 ELISA 
assay was performed for intact (circles) and EDTA‐treated (triangles) 569B OMVs 
using purified CT as a standard (squares). Neither intact nor EDTA-treated OMVs 
bound to GM1. Data are expressed as mean ± SD (N = 3). One‐way analysis of 
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variance followed by Bonferroni's multiple comparison test was used to determine the 
level of significance between samples. No significant difference was found between 
untreated and EDTA-treated OMVs, and a statistically significant difference was 
observed between purified CT and both intact and EDTA-treated OMVs: 12 
comparisons; *p < .05/12 = .004. 
 
To further investigate the identity of the CT fragments, a Western blot analysis was 
performed for 569B OMVs under boiled and reduced conditions. In this experiment, we 
used antibodies against CT, CTA, and CTB to compare their binding to the CT 
polypeptides found in the vesicles. The same volume of CT, CTA, and CTB (10 ng μl-
1) was also used as controls. As expected, the anti-CT antibody detected both CT 
bands in the OMVs (Figure 6.4, i). It also recognized the bands for CTA1 in the CT and 
CTA samples, as well as a band consistent with CTB monomer in the CT and CTB 
samples.  
Figure 6.4, ii demonstrates that the anti-CTA antibody identified both of the CT 
bands that were recognized by the anti-CT antibody. Two faint bands with molecular 
weights of approximately 32 kDa and 8 kDa were also detected. However, because the 
anti-CT antibody did not recognize these two bands, we suggest that they are cross-
reacting bands. Similar to the anti-CT antibody, the anti-CTA antibody recognized the 
CTA1 band in the CTA and CT samples. Additionally, as expected, this antibody did 
not detect the CTB band in the CT and CTB samples. 
As demonstrated in Figure 6.4, iii, in the CT and CTB lanes, the CTB monomer 
strongly reacted to the anti-CTB antibody. The 18 kDa band in the OMV sample and 
the CTA1 in the CT sample were slightly detected by the antibody. As we described 
above, both bands had a strong affinity for the anti-CTA antibody. Therefore, we expect 
that the weak interaction between anti-CTB and these bands is due to a cross-reaction 
because of their high concentration. 
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Together, the results presented here suggest that CTB is not located inside OMVs. 
Only two anti-CTA reactive fragments of CT with molecular weights of 28 kDa and 18 
kDa are enclosed within the lumen of vesicles. As demonstrated before in Figure 6.1, 
lane 3, the 28 kDa band detected in OMVs is non-reducible. Because the proteolytical 
cleavage of CTA occurs after complete secretion, we suggest that this an un-nicked 
form of CTA. Moreover, the epitope of the anti-CTA antibody is located in the CTA1 
subunit (134, 135). Therefore, we propose that the 18 kDa anti-CTA reactive band is a 
fragment of CTA1. For the sake of brevity, in the remainder of this chapter we denote 
the 18 kDa CTA peptide “CTA*”.  
 
Figure 6.4 Composition analysis of V. cholerae 569B OMV-associated CT. Western 
blot analyses of V. cholerae 569B OMVs in the presence of purified CT, CTA, and CTB 
(10 ng ul-1) as standards under boiled and reduced conditions using polyclonal 
antibodies against (i) CT, (ii) CTA, and (iii) CTB. The two anti-CT reactive bands found 
in the OMVs were detected by the anti-CTA polyclonal antibody but were not 
recognized by the anti-CTB antibody. 
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6.2.3 OMVs encapsulate CTA from the periplasmic pool 
Next, we characterized the CT composition of OMVs formed at different growth 
phases to follow the two anti-CTA reactive peptides as they are encapsulated within 
the vesicles. We hypothesized that these peptides might be excess CTA-subunits 
remaining after the holotoxin (CTAB5) assembly reaction in the periplasm, which 
become entrapped in OMVs. To address these questions, periplasm, OMVs, and OMV-
free supernatant fractions of four V. cholerae 569B samples cultured in nutrient broth 
collected from early to late exponential phases (OD600 of 0.25, 0.55, 0.8, and 1.1) were 
extracted. Figure 6.5A demonstrates the growth curve of the bacteria and the selected 
time points. Initially, the quantity of OMVs produced during all phases was quantified 
by the fluorescence of the lipophilic dye, FM 4-64, and was found to increase linearly 
during the growth of the bacteria, demonstrating that OMV secretion is not limited to a 
specific phase of growth. (Figure 6.5B).  
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Figure 6.5 Production of OMVs during V. cholerae 569B growth cycle. (A) Growth curve 
of V. cholerae 569B. Four cultures were grown to an OD600 of 0.25, 0.55, 0.8, and 1.1. 
Selected time points are marked by circles on the growth curve. The line is a guide to 
the eye.  (B) The relative concentration of isolated OMVs produced during the V. 
cholerae 569B growth cycle. The quantity of OMVs was found to increase linearly as 
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measured by the fluorescence of the lipophilic dye, FM 4-64. Data are shown as mean 
± SD (N = 3). 
 
Subsequently, Western blot analyses were performed on the samples from the 
three fractions using a polyclonal anti-CT antibody. Because the CTB5 pentamer is 
heat-sensitive and dissociates upon boiling (Figure 6.1), all analyses were carried out 
under non-boiled and non-reduced conditions to monitor the assembly and 
oligomerization of the subunits and secretion of CT. Samples from the periplasmic 
fractions were normalized by their OD600; therefore, each sample represents the 
periplasm of an average bacterium in each phase.  
Figure 6.6, i, demonstrates the Western blot analysis of the periplasmic fraction. As 
shown in lane 1, two light bands (84 kDa and 68 kDa) along with two major bands (28 
kDa and 18 kDa) were found in the periplasm from the early log phase (lane 1) with a 
decrease in intensity during the later phases (lanes 2 to 4). These bands correspond 
to fully assembled CT, near-assembled oligomer, CTA, and CTA*, respectively. The 
weak intensity of the fully assembled CT and near-assembled oligomer in the periplasm 
supports the reported minimal production of CT in low-salt culture (136, 137). 
Figure 6.6, ii, demonstrates the Western blot analysis of the OMV-free supernatant 
fraction. Two bands with molecular weights of 56 kDa and 28 kDa, corresponding to 
CTB5 pentamer and CTA, respectively, were observed from the early log phase (lane 
2) with a slight increase in intensity over the growth cycle. However, the CTA* band (18 
kDa) we have observed in the periplasm and OMVs was absent in this fraction. The 
two observed bands are consistent with those shown for CT in Figure 6.1 (lane 4); 
therefore, these findings confirm the extracellular secretion of assembled periplasmic 
CT through the T2SS.  
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Figure 6.6, iii, shows the Western blot analysis of the OMV fraction. The CTA and 
CTA* polypeptides were detected with a constant increase in intensity from the early to 
late logarithmic phases. This indicates that the encapsulation of the CTA fragments in 
OMVs is not limited to a specific phase. We reasoned that the weak intensity of the 
CTA* in the OMV fraction in comparison to its strong intensity in the periplasmic fraction 
is due to the inaccessibility of the epitope(s) of the non-boiled CTA* in its native 
conformation within OMVs, as previously shown in lane 1 and 2 of Figure 6.1. This 
weak intensity could be also due to the degradation of the CTA* within the periplasm. 
As observed in section 6.2.1, the CTB5 pentamer was not detected in the OMV fraction. 
This verifies that CT holotoxin is not encapsulated within OMVs.  
Together, these results demonstrate that in nutrient broth cultures of V. cholerae 
encapsulation of CTA into the OMV lumen occurs continuously in the form of two 18 
kDa and 28 kDa peptides in a process that appears to occur alongside the secretion of 
CTAB5 holotoxin via the T2SS.  
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Figure 6.6 Characterization of CT assembly and secretion in V. cholerae 569B. 
Western blot analyses of (i) periplasmic, (ii) OMV-free supernatant, and (iii) OMV 
fractions extracted from four V. cholerae 569B cultures, analyzed under non-boiled and 
non-reduced conditions, using a polyclonal anti-CT antibody. Lanes 1 to 4 represent 
samples with OD600 of 0.25, 0.55, 0.8, and 1.1, respectively. 
 
To investigate if CTA is the excess reactant in the CTAB5 assembly reaction, we 
calculated the CTA:CTB ratio in the periplasmic samples from each growth phase. The 
concentration of CTA and CTB in each sample was measured using two dot blot 
analyses. Periplasmic samples were spotted on two nitrocellulose membranes. In the 
first blot, a serial dilution of CTA was used as standard, and the membrane was 
incubated with an anti-CTA antibody. In the second blot, a serial dilution of CTB was 
used as standard and the membrane was incubated with an anti-CTB antibody (Figure 
6.7A). The intensity of the dots on each blot was then compared with their 
corresponding standards to calculate the mass of each subunit in the samples. Figure 
6.7B demonstrates the estimated total mass concentration of the CT subunits in the 
periplasmic samples.  
 
 
 
64 
 
 
 
 
Figure 6.7 Estimation of the concentration of CTA and CTB-subunits in V. cholerae 
569B periplasm.  (A) Representative dot blot analysis for calculation of (i) CTA 
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concentration in 569B periplasm using purified CTA as a standard and a polyclonal 
anti-CTA antibody and (ii) CTB concentration in 569B periplasm using purified CTB as 
a standard and a polyclonal anti-CTB antibody. Periplasmic dots are labeled from 1 to 
4, representing samples with OD600 of 0.25, 0.55, 0.8, and 1.1, respectively. (B) 
Quantitative analysis of the total CTA and CTB mass concentration in 569B periplasm. 
 
Considering the density of the bands detected in the periplasmic fraction (Figure 
6.6,i), we estimated that, on average, the mass ratio of CTA* (18 kDa):CTA (28 kDa) in 
each phase is approximately 3:1. Based on this assumption and the total estimated 
mass concentration of the CTA subunit, we calculated the concentration of CTA (28 
kDa). As shown in Figure 6.8, the periplasmic 28 kDa CTA:CTB molar ratio during all 
growth phases was greater than 1:1, suggesting that for every pentameric B-subunit, 
at least five A-subunits are present in the periplasm. In other words, for every A-subunit 
that is assembled into an intact AB5 CT for secretion via T2SS, four “excess” A-
subunits exist in the periplasm. We propose that these “excess” A-subunits are 
continuously encapsulated within the OMVs. 
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Figure 6.8 Estimation of the concentration of the 28 kDa CTA and the CTB-subunits in 
the V. cholerae 569B periplasm.  The total mass concentrations of CTA and CTB in the 
569B periplasm at OD600 of 0.25, 0.55, 0.8, and 1.1 were estimated by dot blot 
analyses using anti-CTA and anti-CTB antibodies. The molarity of 28 kDa CTA was 
calculated by assuming that, on average, at least 25% of the mass of the periplasmic 
CTA is in the 28 kDa form. The level of significance was determined using a one‐way 
analysis of variance followed by Bonferroni post-hoc test: 4 comparisons; *p < .05/4 = 
.0125. No significant difference was observed between the CTA and CTB samples from 
OD600 of 0.25, 0.55, and 0.8.   
 
6.2.4 The encapsulation of CTA in OMVs is conserved among OMVs from 
several O1 Inaba strains 
To examine if our findings regarding the encapsulation of the CTA fragments in O1 
Classical Inaba 569B OMVs are conserved among OMVs from O1 El Tor Inaba strains, 
we analyzed the OMVs from N16961 and C6706, the two strains which are responsible 
for the more recent epidemics of cholera. It has been reported that unlike the Classical 
V. cholerae O1 strains which express CT under standard culture conditions, El tor 
strains are reported to be unable to induce virulence under these conditions and require 
more complex growth conditions termed AKI. 
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AKI has two stages during which the bacteria are first cultured in a still tube for 4 hr 
and then the culture is transferred to a flask to continue growth in a shaking mode (138). 
These culture conditions do not resemble the physiological conditions in the small 
intestine. Therefore, the in vivo virulence induction of the El tor biotype is not well 
understood. We hypothesized that the encapsulation of CTA in El tor OMVs might be 
the main route for virulence inductions of the El tor biotype even under the so-called 
“non-virulence inducing” conditions. 
To investigate if our findings on CTA-association with O1 Classical Inaba 569B 
OMVs can be generalized to OMVs from O1 El Tor Inaba strains, we analyzed N16961 
and C6706 OMVs. Cultures were grown in nutrient broth to an OD600 of 1.0, and OMVs 
were purified from each culture. Western blot analysis was performed on the vesicles 
under boiled and reduced conditions using an anti-CT polyclonal antibody (Figure 6.9). 
569B OMVs were used as the control. Similar to 569B vesicles, both CTA and CTA* 
bands were detected in N16961 and C6706 OMVs. The intensity of the bands was 
detected to be stronger in C6706 OMVs than in N16961 OMVs. Moreover, the signal 
detected for CTA* in 569B OMVs was stronger than the signals detected in the other 
two vesicles. A band between 37 kDa and 50 kDa markers was also detected in both 
N16961 and C6706 vesicles which was absent in 569B OMVs. This result suggests 
that the encapsulation of CTA and CTA* (and not AB5 CT) is conserved among studied 
Inaba O1 V. cholerae strains. 
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Figure 6.9 Western blot analyses of V. cholerae O1 Inaba OMVs.  OMVs from 569B, 
N16961, and C6706 strains were analyzed under boiled and reduced conditions. 
Similar to 569B OMVs, intact CT was absent in N16961 and C6706 OMVs. Both anti-
CT reactive bands that were detected in 569B OMVs were found in N16961 and C6706 
OMVs. 
 
Next, we wanted to compare the physiological activity of the OMVs isolated from 
the El tor OMVs with the ones isolated from the Classical 569B strain. Previously, using 
a cell morphology scoring assay, we demonstrated that that similar to soluble CT, the 
569B OMVs change the morphology of small intestinal epithelial cells (123) in a dose-
dependent manner (Figure 4.4). Here, using a similar assay, we wanted to investigate 
whether the N16961 and C6706 OMVs induce a similar cellular response. For this 
reason, the OMVs from each strain were incubated with the FHs 74 Int cells for 3 hr 
and the morphology of the cells was scored on a scale of 1 (spindly) to 4 (rounded), 
based on the percentage of cell rounding.  
We found that similar to 569B OMVs, cell rounding was observed for samples 
treated with both N16961 and C6706 OMVs, confirming the biological activity of the 
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studied El tor vesicles. As demonstrated in Figure 6.10, the C6706 vesicles, which had 
a higher concentration of both CTA and CTA* than the N16961 vesicles, induced a 
greater cellular response. Additionally, the cytotoxicity score of 569B vesicles, which 
has a similar concentration of CTA but a higher concentration of CTA* than the C6706 
vesicles, was greater than that of the other two strains. This finding suggests that the 
OMV-associated CTA* is biologically active.  
 
Figure 6.10 Quantitative analysis of V. cholerae O1 Inaba OMV-mediated 
cytotoxicity.FHs 74 intestinal epithelial cells were treated with isolated OMVs from the 
569B, N16961, and C6706 strains. Control cells were incubated with Hank's balanced 
salt solution. Based on the percentage of cell rounding, the change in cell morphology 
was scored on a scale of 1 (spindly) to 4 (rounded). Data are presented as mean ± SD 
(N = 3). The level of significance was determined using one‐way analysis of variance 
followed by Bonferroni post-hoc test: 3 comparisons; *p < .05/3 = .0167. 
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6.3 Discussion 
CT, the primary virulence factor of the pathogenic strains of V. cholerae, has been 
extensively studied as a free toxin secreted through the T2SS. In chapter 5, we 
demonstrated that in nutrient broth cultures of V. cholerae 569B, a fraction of the 
secreted toxin is enclosed within the 569B OMVs and therefore is not able to be 
detected through the interaction of the toxin with its receptor, GM1 (123). In this 
chapter, we further characterized the structure of the OMV-encapsulated CT and its 
mechanism of association with 569B OMVs grown in nutrient broth culture. 
We first demonstrated that unlike the free, soluble form of the toxin, 569B OMV-
enclosed CT, while biologically active, lacks a mature AB5 multimer structure and 
instead contains two anti-CTA reactive polypeptides. We further investigated the 
assembly and secretion of the periplasmic CT and found that a major fraction of 
periplasmic CTA does not participate in the CT assembly process and instead is 
continuously encapsulated within the OMVs. Additionally, we found that the 
encapsulation of CTA fragments in OMVs is conserved among several Inaba O1 
strains. These results point to a secondary mechanism for the secretion of biologically 
active CT that does not depend on the CTB-GM1 interaction for endocytosis. Together, 
our findings in this chapter indicate that OMVs package a fraction of periplasmic CTA 
within their lumen. This points to a secondary mechanism for the secretion of 
biologically active CT, which does depend on the CTB-GM1 interaction for endocytosis. 
Heat-labile enterotoxin (LT) is another AB5 toxin, closely related to CT, which is 
produced by E. coli. Previous studies on the secretion of LT from V. cholerae have 
demonstrated that LT subunits enter the periplasm as monomers and spontaneously 
oligomerize into the assembled toxin before they travel across the outer membrane 
(139). Additionally, in vitro studies of CT have shown that CTA is capable of binding to 
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B-subunits that are in the assembly process but not to the fully assembled CTB5, 
suggesting that in the periplasmic space, CTA coordinates the CT holotoxin assembly 
by association with the intermediates in B-pentamer assembly (140).  
In agreement with these findings, our results reported here indicate that when V. 
cholerae is cultured in nutrient broth, native and near-native CT in the periplasm is 
secreted as mature (AB5) CT into the supernatant during the early logarithmic phase. 
Additionally, we found that during all growth phases, two major anti-CTA reactive 
polypeptides in the periplasm that were not bound to the oligomeric forms of CTB and 
instead were continuously secreted through OMVs.  
Furthermore, we demonstrated that during all studied phases, the ratio of the 28 
kDa CTA:CTB in the periplasmic space is greater than 1:1. This finding suggests the 
presence of at least five CTA-subunits for every possible CTB5 pentamer in the 
periplasm. Thus, for every mature AB5 toxin that is secreted through T2SS, at least 
four CTA polypeptides are secreted via association with OMVs, as shown in a 
schematic in Figure 6.11.  
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Figure 6.11 Schematic of CTA and CT holotoxin assembly and secretion via T2SS and 
OMVs.  In this schematic, CTB is shown as turquoise circles, CTA (28 kDa) as dark 
blue ovals, and CTA* (18 kDa) as light blue ovals.  Our results demonstrate that when 
V. cholerae 569B is cultured in nutrient broth, AB5 holotoxin is found in the periplasm 
and OMV-free supernatant but not in OMVs.  Instead of holotoxin, the OMVs contain 
only CTA polypeptides, which are biologically active.  In the periplasm, the CTA 
concentration is approximately the same as that of CTB, indicating that for every AB5 
holotoxin secreted via the T2SS, four biologically active CTA-subunits are secreted via 
OMVs. 
 
In spite of numerous studies on the wide range of exoproteins recognized by the 
T2SS, little is known about the secretion signal that mediates the translocation of 
proteins across the outer membrane (141). Studies about LT secretion from V. cholerae 
have shown that the A-subunit can accelerate the B-subunit pentamerization in the 
periplasm (140), while in the absence of A-subunit, the B-subunit is still able to be 
assembled into a stable pentamer and be secreted through the T2SS apparatus. 
However, in the absence of the B-subunit, the A-subunit has not been found to be 
secreted into the medium, suggesting that the secretion signal of LT resides in the B-
subunit (40, 142).  
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Recent electron microscopy analyses also confirmed that CTB5 can bind to the 
entrance of the periplasmic vestibule of the secretin GspD, the major T2SS outer 
membrane protein in V. cholerae (143, 144). On the other hand, Connell et al. have 
proposed that for both LT and CT, the transport signal is instead a conformational motif 
within the native or near-native structure of the secreted toxin (145).  
Our finding of two assembled and near-assembled oligomers in the periplasm, 
which are later secreted into the supernatant as CTAB5, is in agreement with previous 
studies that the CT secretion signal resides in the B-pentamer. Furthermore, the 
continuous encapsulation of the 28 kDa periplasmic CTA in OMVs, especially after the 
late logarithmic phase, where all of the CT and near CT bands are absent in the 
periplasm and no more CT is secreted in supernatant, indicates that in the absence of 
the CTB-pentamer, CTA lacks a secretion signal to be translocated individually across 
the outer membrane. Instead, CTA along with the periplasmic CTA* appears to be 
constantly packaged into OMVs and secreted through this pathway. Given that a 
majority of periplasmic CTA is secreted through OMVs, it is conceivable that CTA 
contains a signaling motif that enables packaging within the budding OMV through a 
secondary mechanism.  
In laboratory-grown cultures of V. cholerae, secreted CT normally becomes 
enzymatically activated by extracellular proteases, which cleave CTA at the nick site, 
Arg-192 (41). Hemagglutinin/protease (HAP), VesA, and VesB are three proteases 
secreted through the T2SS that have been demonstrated to contribute to proteolytic 
cleavage of secreted CT; inhibition of these enzymes has been demonstrated to result 
in the secretion of un-nicked CT (146, 147). However, Lencer et al. have shown that 
endogenous proteases of the host cell are able to activate endocytosed CT, and 
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processing of the A-subunit by V. cholerae proteases prior to its internalization in host 
cells may not be essential in vivo (148).  
In light of these findings, we suggest that the reason that the OMV-associated 28 
kDa, anti-CTA reactive polypeptide is unable to be reduced to CTA1 under boiled and 
reduced conditions is that the CTA packaged within the vesicles is un-nicked, possibly 
due to the absence of bacterial proteases in the periplasmic space that are able to 
cleave CTA at residue Arg-192.  
Additionally, we detected an 18 kDa, non-reducible, anti-CTA reactive peptide 
(CTA*) in both the periplasm and vesicles of 569B strain, which, similar to CTA, was 
conserved among the studied El tor and Classical strains of V. cholerae. We reasoned 
that because the epitope recognized by the anti-CTA antibody resides within the CTA1 
subunit (134), the CTA* is a fragment of CTA1. Our finding that the 569B OMVs, which 
contain a similar concentration of CTA but a higher concentration of the CTA*, induce 
a greater morphological response than the C6707 OMVs suggests that this peptide has 
biological activity.  At this point, it is not clear how CTA degrades to form these CTA1 
fragments. One possible mechanism could be the partial cleavage of periplasmic CTA 
by unknown periplasmic proteases, which nick CTA at an alternative site.   
A number of studies have demonstrated the association of various virulence factors 
with OMVs either on their outer surface or within their lumen. In ETEC, the OMV-
associated LT has been found to partially reside inside the OMVs, while another 
fraction of the toxin is located on the surface of the OMVs (121). Horstman et al. have 
demonstrated that the partial association of the toxin with the outer surface of OMVs is 
due to the LT-LPS interaction upon the secretion of LT through the T2SS (112). 
Moreover, an early study on periplasmic LT has shown that only about 50% of the 
periplasmic pool of free LTA associates with LTB to form LT holotoxin  (149). Based on 
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these studies and our findings, we propose that the intravesicular LT, similar to CT, is 
mainly composed of the A-subunit and that V. cholerae and ETEC share a similar 
process in packaging the biologically active periplasmic A-subunit within their vesicles.  
In summary, our results in this chapter, indicate that OMVs package a fraction of 
periplasmic CTA within their lumen. This points to an independent mechanism, that 
relies on OMVs for the secretion of biologically active CTA instead of an interaction of 
the CTB-pentamer with the T2SS machinery.  
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Chapter 7  
 
The Effect of Physiological Conditions on Association 
of CT with 569B OMVs 4 
 
7.1 Introduction  
When V. cholerae enters the small intestinal region, it encounters different 
environmental factors including bile salts, osmolarity, bicarbonates, and pH variations 
(24-26). These factors regulate the expression of virulence factors in V. cholerae. 
Previous studies have reported the importance of the intestinal cues on the secretion 
of free CT. In the previous chapters, we demonstrated that in addition to secreting CT 
in the soluble AB5 form, V. cholerae secretes biologically active CTA polypeptides 
through encapsulation inside the OMVs. Because this form of the toxin is not 
recognizable through standard CT-detection assays based on GM1 binding, it is 
important to study the impact of the host environment parameters on the association of 
the toxin with OMVs as well.  
In this chapter, we aim to describe the impact of two host signals, osmolarity and 
bile salt, on the association of CT with OMVs. It has been previously reported that 
Classical biotype strains of V. cholerae O1 produce CT in a NaCl-dependent manner 
(136, 137). Here, we continued our studies with the V. cholerae 569B strain cultured in 
a nutrient broth medium under a range of osmolarities to investigate the association of 
specific CT subunits with OMVs and further characterize this important delivery system.  
 
4 Portions of this chapter appear in a published work and are presented with permission 
from MDPI. 132. Ibid. 
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Additionally, we investigated the impact of bile salt on the association of CT with 
OMVs. Bile salts are the major components of bile. Bile acids are cholesterol 
derivatives that are synthesized in the liver and are secreted in the duodenum (the 
proximal segment of the small intestine) (150). The major bile salts found in the small 
intestinal region are sodium salts of cholic acid, deoxycholic acid, 
chenodeoxycholic acid, and lithocholic acid with a physiological concentration in the 
range of 0.2 to 2% (wt/vol) (151, 152). The primary role of bile in the lumen of the 
small intestine is to facilitate fat digestion. Because of their detergent-like activity, bile 
salts also function as antimicrobial agents by damaging bacterial cell membranes 
(153). Moreover, bile salts act as environmental cues controlling virulence factor gene 
expression (154). Hung and Mekalanos have found that V. cholerae secretes less CT 
in the presence of bile salts (155). However, no studies have been performed on the 
impact of bile salts on the association of CT with OMVs.  
On the other hand, studies on bacterial OMVs have shown that stress conditions 
such as an increase in temperature, oxidative stress, antibiotics exposure, and nutrient 
depletion regulates the secretion of OMVs (74, 90, 95, 156, 157). However, limited 
studies have investigated the influence of host-specific signals on the production of 
OMVs. A recent study on Campylobacter jejuni has demonstrated that the bile salt 
sodium taurocholate induces OMV production (158). In this chapter, we investigated 
the impact of the bile salt sodium cholate (SC) as an environmental signal in the small 
intestine on the production and characteristics of V. cholerae OMVs. 
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7.2 Results 
7.2.1 The effect of osmolarity of the growth medium on the association of CT 
with 569B OMVs  
Previous studies on V. cholerae Classical strains have demonstrated that the 
extracellular secretion of CT is regulated by the level of NaCl in growth medium (136). 
Using a GM1-ELISA assay, Gardel et al. (137) have demonstrated that the optimal 
NaCl concentration for total CT secretion in various Classical strains is in the range of 
60-100 mM. Because our studies so far have been performed in the nutrient broth, 
which is low in salt, we wanted to analyze whether a change in osmolarity of the growth 
medium influences the CT association with OMVs as well as CTA encapsulation within 
the vesicles.  
Therefore, V. cholerae 569B was grown to an OD600 of 1.0 in standard nutrient broth 
and nutrient broth containing 85.5 mM NaCl, and OMVs and OMV-free supernatant 
fractions were then collected. To quantify the CT concentration in each sample, a GM1 
ELISA assay was performed using a serial dilution of CT as a standard and an anti-CT 
polyclonal antibody. As shown in Figure 7.1 and demonstrated previously, under the 
low-salt culture condition, no signal was detected for CT on the surface of OMVs and 
a low concentration of CT was found in the OMV-free supernatant fraction. As 
expected, under the NaCl-rich condition, the concentration of CT in the OMV-free 
supernatant fraction increased significantly. Surprisingly, we found that approximately 
40% of the secreted CT was associated with the surface of OMVs. This result indicates 
that the osmolarity of the growth medium has a great impact on the association of CT 
with the surface of OMVs.  
 
 
79 
 
`  
Figure 7.1 Effect of medium osmolarity on the association of CT with OMVs.  A GM1 
ELISA was performed for OMVs and OMV-free supernatant fractions purified from 
either low-salt or 85.5 mM NaCl-containing 569B growth medium. The increase in salt 
concentration in the growth medium increased the secretion of CT in the free form 
(OMV-free supernatant), as well as on the surface of the OMVs. Data are shown as 
mean ± SD (N = 3). The level of significance was determined using one‐way analysis 
of variance followed by Bonferroni post-hoc test: 2 comparisons; *p < .05/2 = .025. 
 
7.2.2 The encapsulation of CTA in OMVs increases with an increase in the 
culture osmolarity 
Next, to investigate if the culture osmolarity affects the encapsulation of CTA within 
OMVs, an indirect ELISA assay was performed using an anti-CTA polyclonal antibody, 
as described previously (123). In this assay, an ELISA plate was coated with a serial 
dilution of either intact or EDTA-disrupted OMVs from low-salt and salt-rich cultures. 
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To quantify the intravesicular CTA concentration, the difference between the signals 
detected for the disrupted and intact vesicles was calculated for each condition. As 
shown in Figure 7.2A, the signal increases in a dose-dependent manner for both OMVs 
grown in low-salt and salt-rich conditions, indicating that CTA is present within the 
lumen of the OMVs. A greater dose-dependent signal was detected for OMVs grown 
under salt-rich conditions, suggesting that an increase in the osmolarity of the culture 
leads to greater encapsulation of CTA fragments within the vesicles in addition to the 
observed increase in CT association with the surface of the vesicles. 
Next, we wanted to investigate whether CTB is encapsulated within the vesicles 
under salt-rich culture conditions. For this reason, a GM1 ELISA was performed using 
an anti-CT antibody to compare the CTB concentration in intact and EDTA-disrupted 
OMVs from a salt-rich culture. A serial dilution of CT was also used as a standard. 
Figure 7.2B demonstrates that, as expected, CTB is associated with the surface of the 
intact vesicles. However, no increase in CTB concentration was detected in the 
disrupted OMVs. Together, these results indicate that the encapsulation of CTA within 
the vesicles increases with an increase in osmolarity of the growth medium. However, 
under neither low-salt nor salt-rich conditions is CTB encapsulated within the OMVs. 
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Figure 7.2 The effect of osmolarity on encapsulation of CT subunits with OMVs. (A) 
Comparison of CTA encapsulation in 569B OMVs from cultures grown in either low-
salt (triangles) or 85.5 mM NaCl-containing growth medium (squares). Indirect 
noncompetitive ELISA was performed for intact and EDTA‐disrupted 569B OMVs and 
the difference between the binding to anti-CTA polyclonal antibody was calculated to 
measure the intravesicular CTA signal. More CTA was detected in the lumen of vesicles 
isolated from salt-rich medium than in the lumen of vesicles isolated from low-salt 
medium. Data are expressed as mean ± SD (N = 3). (B) GM1 ELISA of intact and 
EDTA‐disrupted 569B OMVs under salt-rich conditions using purified CT as a standard. 
No increase in the concentration of CTB was found for EDTA-treated OMVs. Data are 
presented as mean ± SD (N = 3). No significant difference was observed between the 
two samples as determined by an unpaired two‐tailed t test. 
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7.2.3 Effect of SC on the growth of V. cholerae 569B 
Next, we wanted to evaluate the impact of bile on V. cholerae 569B OMVs. Because 
bile salts have an inhibitory impact on the growth of bacteria, we first investigated the 
effect of SC on the viability of the bacterium. V. cholerae 569B was precultured in 
nutrient broth (85.5 mM NaCl) until the late logarithmic phase. The media containing 
0.05% to 0.8% SC were further inoculated with 1:100 of the starter culture. As 
demonstrated in Figure 7.3, SC levels above 0.1% decreased bacterial viability 
significantly. Therefore, we continued this study in nutrient broth containing 85.5 mM 
NaCl and 0.1% SC.   
 
Figure 7.3 Effect of the bile salt SC on the growth of V. cholerae 569B.  Cells were 
cultured in presence of different concentrations of SC. Growth inhibition was detected 
in media with SC levels above 0.1%. Data are shown as mean ± SD (N = 3). 
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7.2.4 Bile salts decrease the number of OMVs secreted from V. cholerae 569B  
To investigate the effect of SC on V. cholerae 569B OMVs, cells were cultured to 
an OD600 of 1.0 in the presence and absence of 0.1% SC. OMVs were isolated from 
each culture as described before (123). Dynamic light scattering was used to measure 
the size of secreted vesicles. As demonstrated in Figure 7.4A, OMVs released in 
presence of SC were found to be slightly larger than those secreted under the control 
condition. The fluorescent dye FM-64 was also used to measure the lipid concentration 
of OMVs under each condition. The relative number of vesicles secreted in the 
presence and absence of SC was further calculated as described previously (123). 
Figure 7.4B demonstrates that fewer OMVs are produced in the presence of the bile 
salt SC. 
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Figure 7.4 Effect of the bile salt SC on OMV production of V. cholerae 569B.(A) The 
effect of SC on the size of OMVs. Larger OMVs were released in presence of the SC 
as measure by the DLS. (B) The relative concentration of isolated OMVs produced in 
presence and absence of SC. The quantity of OMVs was found to decrease in presence 
of SC as measured by the fluorescence of the lipophilic dye, FM 4-64. Data are 
demonstrated as mean ± SD (N = 3). The level of significance was determined using 
one‐way analysis of variance followed by Bonferroni post-hoc test: 2 comparisons; *p 
< .05/2 = .025.  
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Additionally, the effect of SC on the total protein concentration of the OMVs was 
investigated using the bicinchoninic acid (BCA) assay. As shown in Figure 7.5, the total 
protein concentration of 569B OMVs was also decreased in the presence of SC.  
 
Figure 7.5 Effect of SC on the protein concentration of 569B OMVs. The protein 
concentration of the OMVs decreased in presence of SC. Data are presented as mean 
± SD (N = 3). The level of significance was determined using one‐way analysis of 
variance followed by Bonferroni post-hoc test: 2 comparisons; *p < .05/2 = .025. 
 
7.2.5 Effect of bile salts on the association of CT with 569B OMVs 
Next, we characterized the effect of bile salts on the association of CT with OMVs. 
Previously, we demonstrated that CT is associated with 569B vesicles in two forms, 
the surface-associated CT holotoxin (CTAB5) and the OMV-encapsulated CTA. To 
determine the impact of SC on the level of surface-associated CT, a GM1 ELISA assay 
was performed as described previously (121). Briefly, a GM1-treated 96-well plate was 
treated with OMVs produced in the presence and absence of SC as well as a serial 
dilution of purified CT as a standard. The concentration of CT on the surface of OMVs 
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was then quantified using an anti-CT polyclonal antibody. As demonstrated in Figure 
7.6A, SC slightly decreased the concentration of OMV surface-associated CT.  
Additionally, to investigate the effect of SC on encapsulation of CTA within vesicles, 
an indirect ELISA assay was performed using an anti-CTA polyclonal antibody, as 
described before (123). A serial dilution of intact or EDTA-treated vesicles produced 
under each condition was added to an ELISA plate. The plate was incubated with the 
primary and secondary antibodies. The difference between the subsequent signals for 
disrupted and intact vesicles was then measured to estimate the CTA concentration 
within the vesicles. As shown in Figure 7.6B, a dose-dependent increase in the signal 
was found for both samples, confirming the presence of CTA inside the vesicles. The 
signals detected for OMVs produced in presence of SC were found to be less than the 
signals for OMVs isolated under control condition suggesting that SC decreases the 
concentration of CTA encapsulated within 569B OMVs.   
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Figure 7.6 Effect of SC on the association of CT with 569B OMVs. (A) GM1 ELISA for 
569B OMV-associated CT. Concentration of CT on the surface of OMVs were 
measured. Exposure to SC in 85.5 mM NaCl containing nutrient broth culture had no 
significant impact on association of CT with surface of vesicles. Data are expressed as 
mean ± SD (N = 3). No significant difference was observed between two samples as 
determined by an unpaired two‐tailed t test. (B) Comparison of CTA encapsulation in 
569B OMVs from 85.5 mM NaCl containing nutrient broth cultures grown in presence 
(squares) or absence (triangles) of SC. Indirect ELISA was carried out for intact and 
EDTA‐disrupted 569B OMVs and the difference between the binding to anti-CTA 
polyclonal antibody was calculated to measure the intravesicular CTA signal. The 
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concentration of CTA encapsulated within the vesicles slightly decreased in presence 
of SC. Data are expressed as mean ± SD (N = 3). 
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7.3 Discussion 
V. cholerae encounters a variety of environmental signals in the small intestine 
including a shift in the level of bile, sodium bicarbonate, osmolarity, and pH (24-26). 
The impact of these factors has been previously studied on the free soluble form of CT 
(136, 137). However, to the best of our knowledge, no studies have been conducted to 
investigate the impact of these factors on V. cholerae OMVs and the association of CT 
with them. In this chapter, we studied the impact of two of these factors, osmolarity and 
bile salt, on OMV-associated CT. We first demonstrated that the addition of salt to the 
culture not only increases the secretion of CT in free form but also results in the 
localization of extracellularly secreted CT holotoxin (AB5) on the surface of OMVs as 
well as encapsulated-CTA within the OMV. Next, we investigated the effect of a bile 
salt, SC, on the association of CT with 569B OMVs cultured in an 85.5 mM NaCl-
supplemented nutrient broth. We found that while exposure to bile has no significant 
impact on the association of CT with OMVs, it decreases the production of OMVs and 
their total protein concentration.  
Our findings described in chapter 5 demonstrated that CT does not have any affinity 
for V. cholerae 569B LPS isolated from a low-osmolality nutrient media. Thus, it does 
not bind to the outer surface of the OMVs after secretion (123). Our results here, 
however, demonstrate that under high osmolarity conditions, extracellularly secreted 
CT binds to the surface of OMVs. It has been reported that salt stress may alter the 
bacterial LPS structure (159, 160). We, therefore, propose that an increase in the salt 
level of the growth medium changes the structure of the V. cholerae LPS, and the 
interaction of CT with this modified LPS might lead to the association of CT with the 
surface of vesicles.  
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Previous studies have suggested that the OMV production increases under stress 
conditions. For example, oxidative stress has shown to increase the production of 
OMVs in Pseudomonas aeruginosa and Neisseria meningitidis (161, 162). Antibiotic 
exposure has found to promote the secretion of OMVs from P. aeruginosa (163). A 
55°C heat shock in E. coli and Pseudomonas putida resulted in a significant increase 
in the release of OMVs (89, 164). On the other hand, temperature elevation from 25°C 
to 39°C in P. aeruginosa did not increase the production of OMVs (161), suggesting 
that temperature impact on  OMV biogenesis is species-specific.  
A recent study has investigated the effect of bile salt on C. jejuni OMVs and has 
found that the bile salt sodium taurocholate increases the production of OMVs and their 
proteolytic activity (158). Our finding that SC decreases the secretion of V. cholerae 
OMVs is in contradiction with the aforementioned report and suggests that the effect of 
bile on OMV production might be species-dependent. Therefore, further studies are 
required to investigate the effect of this factor on the formation of OMVs.  
Together, our results in this chapter suggest that while osmolarity has a great 
impact on CT association with OMVs, the effect of bile seems to be negligible. We 
propose that three forms of biologically active CT can be found under high-osmolarity 
conditions; the well-studied free CT that is secreted extracellularly, the OMV-surface 
associated CT, and the OMV-encapsulated form which only constitutes the CTA 
fragments (Figure 7.7). Our studies under low-osmolarity conditions suggest that the 
latter does not require the CTB-GM1 interaction for endocytosis and only relies on 
OMVs for host-cell entry. Therefore, OMV-association might be a secondary strategy 
of the bacteria to deliver active CT to host cells. 
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Figure 7.7 Schematic of the proposed mechanism of CTA and CT holotoxin assembly 
and secretion via T2SS and OMVs under low-salt and salt-rich conditions. In this 
schematic, CTB is shown as turquoise circles, CTA (28 kDa) as dark blue ovals, and 
CTA* (18 kDa) as light blue ovals. Our results demonstrate that an increase in the 
osmolarity of the culture results in an increase in the secretion of CT through both T2SS 
and OMVs. We propose that three forms of CT can be found under salt-rich conditions; 
(1) the free, soluble CT, (2) the OMV-surface associated CT, and (3) the OMV-
encapsulated CTA. 
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Chapter 8  
 
Conclusions and Future Work 
 
In this work, we studied the association of CT with V. cholerae OMVs with the goal 
of understanding the role of the toxin in the mechanism of OMV delivery to the host 
cells. We found that when V. cholerae 569B was cultured in nutrient broth, no CT was 
located on the surface of OMVs and biologically active OMVs were internalized in a 
CT-GM1 independent mechanism. While CT holotoxin was absent in OMVs under this 
condition, we found that OMVs package a fraction of periplasmic CTA within their lumen 
in the form of two 18 kDa and 28 kDa peptides. We next studied the association of CT 
with two O1 El Tor Inaba strains, N16961 and C6706, and found that our findings 
regarding the encapsulation of CTA within the vesicle is conserved among these 
studied strains.  
Additionally, we investigated the impact of environmental factors found under in 
vivo conditions and found that the osmolarity of the growth medium has a great impact 
on association of CT with OMVs. Our results demonstrated that an increase in the 
osmolarity of the medium not only increases the secretion of CT in free form but also 
results in the localization of extracellularly secreted CT holotoxin (AB5) on the surface 
of OMVs as well as encapsulated-CTA within the OMV. 
Our studies under low-salt conditions demonstrated that free soluble CT has no 
affinity for 569B OMVs and LPS, the major component of the surface of the vesicles. 
Therefore, we propose that association of CT with the surface of OMVs under salt-rich 
conditions is due to a change in the structure of LPS. Characterization of the binding 
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of CT to isolated 569B LPS or OMVs purified from non-expressing CT strains of V. 
cholerae under salt-rich conditions would allow for a better understanding of this 
interaction. 
Our studies under low-salt conditions demonstrated that the host cell internalization 
of OMVs occurs even in absence of CT on the surface of the vesicles. However, it is 
not clear whether CT located on the surface of OMVs under salt-rich conditions plays 
a role in the host cell uptake of the vesicles. Therefore, further studies are required to 
investigate the role of CT-GM1 interaction on endocytosis of OMVs under salt-rich 
conditions and to determine whether blocking this interaction would inhibit the delivery 
of the OMV-encapsulated CTA or not.  
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